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A brief history .... 
One day my dad was playing golf, which isn't that unusual, and 
noticed his golf swing was slightly off, which also is not that unusual. 
However, on this occasion his leg was cramping and stiff, so he went to 
the doctor for an examination. Sure enough the doctor found an arterial 
blockage and dad underwent the conventional drug therapies. Within a 
few months he was back on the greens again. 
Throughout this experience he encouraged me to develop a more 
effective therapy for golfers with blockages that impair golf swings. He 
was convinced that I could do it. Little did he realize that I had just 
graduated with a degree in physical chemistry, not medicine. (In my 
family, if you do science you are either a rocket scientist or are trying to 
cure cancer.) However, a short time later the faculty lectures to the first 
year graduate students began (during the baseball playoffs!). John gave his 
lecture about tumors in rats and curing cancer and clots, and I knew I was 
being offered a great opportunity. In addition to finding a thesis topic, I 
could cure dad and the myriad of golfers with his affliction. He was 
thrilled! 
There are many people who I would like to thank for helping me 
attain my Ph. D. degree. I am sincerely grateful to John Baldeschwieler for 
his guidance and to all the people in the JDB group for their friendship 
and Tuesday lunches at restaurants too exotic for Carl. I would especially 
like to thank Van for being a mentor, colleague and friend. 
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members, who have encouraged me and are a great source of happiness. I 
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Liposomes have been used to deliver diagnostic and therapeutic drugs 
with moderate success. Current applications include targeting to tumors 
(1) , where the vasculature is leaky and allows liposome penetration, and 
Kupffer cells in the liver (2). Reticuloendothelial system (RES) uptake and 
lack of targeting specificity of the liposomes have been the major problems 
encountered. Several groups including Allen et al. (3) and Liu et al. (4) 
have increased the circulation times by attaching polyethylene glycol (PEG) 
or the ganglioside GMt to the liposome surface; the circulation half-lives 
for disteroylphosphatidylcholine (DSPC) :cholesterol:PEG and GMt 
liposomes are 20.0 ± 3.5 and 16.4 ± 3.1 hours, respectively as compared to 
6.7± 4.5 hours for DSPC:cholesterol (2:1 mole ratio) liposomes (3). In 
addition, some attempts have been made to target specific areas by the 
addition of ligands, such as human gamma globulin or aminomannose; 
however this increased targeting has been largely limited to increased 
Kupffer cell and RES uptake (5, 6). Addition of antibodies to the liposomes 
increases targeting specificity, but has met with limited success since the 
liposomes are still prone to RES uptake (7). 
Reconstituted Sendai virus envelopes (RSVE) are essentially liposomes 
with binding and fusogenic glycoproteins on their surface. These vesicles 
have been used as vehicles for delivering molecules into cells in vitro 
and for the transfer of membrane proteins into the cells' plasma 
membranes. Similar to intact viruses, RSVE attach preferentially to cells 
having the appropriate receptors, usually gangliosides, and fuse with the 
cellular membranes, thus emptying their contents into the cell cytoplasm. 
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This also results in the implantation of the viral envelope components 
into the recipient cell plasma membrane. 
We have studied the in vitro interactions of small unilamellar 
vesicles (SUV) and reconstituted Sendai virus (RSVE) with platelets with 
the objective of developing new drug delivery systems. Specifically, we 
have examined the kinetics and mechanisms of uptake of SUV, with and 
without covalently attached proteins, and RSVE. Liposomes that have 
been studied include: DSPC:cholesterol (2:1 mole ratio) liposomes 
(control) (8) and aminomannose (Am), human gamma globulin (HgG) 
and transferrin (Tf) labeled control liposomes (9). From our data we 
conclude that the mechanisms and kinetics of uptake and subsequent 
specific localization of the lipid and aqueous components of the liposomes 
within the cells are dependent on the type of liposome used. 
Platelets have the unique ability to target to specific areas in vivo 
including areas of infection and inflammation, tumors and clots . 
Therefore we hoped to combine this in vivo targeting ability with the 
platelets' ability to take up liposomes and RSVE in vitro to create new 
drug delivery systems to deliver diagnostic and therapeutic reagents. 
Having a variety of systems from which to choose should offer the ability 
to optimize drug delivery parameters. 
In vitro functional assays, including microaggregation, serotonin 
release and membrane integrity, conclude that platelet function is not 
inhibited by liposome uptake (8, 9). However, uptake of intact and 
reconstituted Sendai virus particles induce platelet aggregation and 
secretion. In vivo organ distribution studies in Sprague-Dawley rats 
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indicate that circulation times and RES uptake of liposorne-loaded rat 
platelets are identical to control rat platelets (10). 
vi 
1. Forssen, E. A., Coulter, D. M. and Proffitt, R. J. (1992) Cancer Res. 52, 
3255-3261. 
2. Derksen, J. T. P., Morselt, H. W . M. and Scherphof, G. L. (1988) Biochim. 
Biophys. Acta 971, 127-136. 
3. Allen, T. M. and Hansen, C. (1991) Biochim. Biophys. Acta 1068, 133-
141. 
4. Liu, D. and Huang, L. (1990) Biochim. Biophys . Acta 1022, 348-354. 
5. Derksen, J. T. P., Morselt, H. W. L. and Scherphof, G. L. (1987) Biochim. 
Biophys. Acta 931, 33-40. 
6. Proffitt, R. T., Williams, L. E., Presant, C. A., Tin, G. W ., Uliana, J. A., 
Gamble, R. C. and Baldeschwieler, J. D. (1982)Science 220, 502-505. 
7. Torchilin, V. P., Klibanov, A. L. and Huang, L. (1992) FASEB f. 6, 2716-
2719. 
8. Male, R., Vannier, W. E. and Baldeschwieler, J. D. (1992) PNAS 89, 
9191-9195. 
9. Male, R., Vannier, W . E. and Baldeschwieler, J. D. (1992) FASEB f. 6, 
A1597. 
10. Male, R., Garvey, J. S., Vannier, W. E., Moon, D~ J. and 
Baldeschwieler, J. (1993) FASEB J. 7, A657. 
vii 
viii 
TABLE OF CONTENTS 
ACKNOWLEDGMEN'TS........... ......... ............................... ............... .......... ... ii 
ABSTRACT ......... ......... .... ....... ... .. ...................... .... ....... ... ........ ......................... iv 
TABLE OF CONTENTS ..................... .... .......... ....... .. ........... ................. ......... viii 
INTRODUCTION ..................... .............. ........ .................... ..... ...... ............ .. .. .. 1 
Drug Delivery Systems... ......... ............ .... .............. ............... .. .... .. 2 
Platelets .................. ............ .......... .... ..... ............. ....... ..... ...... ............ 5 
Platelet Formation ................... .. ........ .... .. ..... ............. ........ 5 
Platelet Morphology .............. ...................... .... ............... ... 6 
Haemostasis .......... ................. ......... .. ........... .... ................. .. 8 
Senescence of Platelets ....... ..... ............. ..................... ........ 11 
References ...... ............. ............... ... ............. ...................... ... 13 
Liposomes.... .. .. ..... . .. .. . .. ........ .. ... .. .. .. .. .. .. . ....... .. ... .. . .. .. . .. ... ....... .. .. . .. . 21 
Introduction........ .. .......... ..... .. .... .......... ........... ..... .... ... ... .... 21 
Liposomes In vivo. .......... ... .. .................. .. ........................ 22 
References .... ....................... ................. ........ .... ... ..... ........ ... 24 
Sendai Virus .. .................... ............. ................. .. ......... ............. ...... 26 
Introduction .............. ... .............................. ...... .. .. ........ ..... .. 26 
Reconstituted Sendai Virus Envelopes.... ...... .... .......... 27 
References. .. .. ............ ............ ......... .. ............... .......... .... .. .... 28 
PHAGOCYTOSIS OF LIPOSOMES BY HUMAN PLATELETS.......... .... 33 
Abstract....... ..... ............. .......... .... ...... ... ........... .......................... ....... 34 
Introduction ........ ....... ........ ....... .. ..... ....... ............. ........ ..... .. ....... ..... 34 
Materials and Methods ............................. .......... ... ................. ...... 35 
Results ........... ... ............. .............. ....... ..... ....................... .. ................ 41 
Discussion...................................... ........................ ............ ........ ..... 45 
Acknowledgments ........... .............. .. ... ................... .... ... ............ .... 48 
References....................... ... ....................................... ...................... 49 
KINETICS OF LIPOSOME UPTAKE BY HUMAN PLATELETS.. ......... 65 
Abstract. ....... ........... ........ .... .......... .. .. ........... ...... ...... ...... .................. 66 
Introduction ...... .... ............................... ...... ........... ..... .... ..... ...... ...... 66 
Materials and Methods ....... .. ........ .... ............ .. .............. .... ............ 67 
Results ...... ...... .... ... .......... ... ...... ... ................ .... .. ... ... ..... ............... ..... 67 
Discussion ...... ...................... ...... ..... ... ......... ................. ........... ........ 69 
References .............................................................. ...... ............. ...... 70 
ORGAN DISTRUIBUTIONS OF LIPOSOME-LOADED 
PLATELETS...................................... .... ........... ............... ............. .......... ........... 79 
Abstract.. ...... ......... ........ ................ .. .. .... ..... ... ... ......... .. ....... .............. 80 
Introduction ...... ........... ............. .. ....... ..... ....... ..... ........ .... ............... . 80 
Materials and Methods ... ... .... .. ....... .. ...... .... ... ............... ........ ........ 82 
Results ............ .. ..... ........ ...................... ... .. ............... ... ..... .. ........ .. ..... 85 
Discussion.... ..... ....... ........................................ ............ ... ... ...... ....... 86 
Acknowledgments .... ... .. ....... ... ..... ......... .... ... ...... ........ ... ..... .. ........ 87 
References....... ........... .. ......... ..... .... .... .................... ......................... 88 
UPTAKE OF LIPOSOMES WITH COVALENTLY ATTACHED 
LIGANDS BY HUMAN PLATELETS ................ ... .. ............... .... ... .... ... ..... ... 94 
Abstract..... ... ....................... ............... ... .. .... .. ................ ................... 95 
Introduction ... ............................................... ..... ....... ..... ......... ........ 95 
Materials and Methods ............. ...... .. .. ................. ..... ............ ... ..... 96 
Results ....................... ..... ....... ......... ......... ..... ............ ...... ...... ........ .... 100 
IX 
X 
Discussion. ........ ............... ....... .............. ....... .. .. ...... .... .............. .. ..... 104 ·. 
Acknowledgments .... .. ...... ....... ...... ... ....... ............ ..... ........ .. .......... 106 
References....... .. ................ ..... ........ .. .... .. ... ... ..... ...... ........ ... .... .... .... . 107 
CHARACTERIZATION OF THE INTERACTION OF 
PLATELETS WITH SEND AI VIRUS.. ................. .. .... ...... .... ...... .. ...... ........ 136 
Abstract.......... .... ......... ........ .... .... ........ .... .. .... .... ................. ..... ...... .. . 137 
Introduction ...... .... .. ........... ... ... ........ .... ... ............ .. ........ ....... ..... ... ... 137 
Materials and Methods ... .... ...... ....... .......... .. .. ..... .... .. .. ........... .. ..... 139 
Results ...... .......... ....... ... ........... .............. ......... ....... ....... ..... ....... ...... .. 146 
Discussion.... .... ......... ..... .... .......... ...... ...... ... ... .. ... .. ... ..... .. ..... ..... ...... 152 
Acknowledgments ......... .. ...... .. ... ... ... .... .... ........ .. .... ... ... ......... ....... 155 
References.. .. .. ...... .. .... .... ........ .... .. ....... .... ..................... .. ...... ... ........ 156 
ASSESSMENT OF THE THROMBOLYTIC EFFICACY OF 
LIPOSOME ENCAPSULATED STREPTOKINASE ........ .... .... .... ...... .. .... ... 173 
Abstract ....... .............. .................................................................. .... . 174 
Introduction ...... ............... ... ..... ... ......... .... ..... ... ..... ... .... ..... ... ... ... .... . 174 
Materials and Methods.. ...... ........ ... .... .......... ... .... .... ... .. .............. . 176 
Results ......... .. ............. ....... ..... ..... ... .. .... ...... ........... ........ .. ... ..... ......... 178 
Discussion ........ ..... .. ... ... ... .. .. ..... ... .. ...... .... .... .... ... .. ... .. .. .. ....... ......... . 179 
References....... .. .... .... ...... .. ...... .. .. .. ......... ... ....... ....... .. ....... .. .. ... ..... ... 181 
xi 
USEFUL ASSAYS FOR THE JOB GROUP .. ... ............ .. ........... ..... ........ ....... 186 
Bottcher Modification of the Barlett Phosphate Asssay ..... ... 187 
Peterson Modification of the Lowry Protein Assay ... .. .... ..... .. 187 
Sendai Virus Preparation...... .... .... ... ... .... .......... .. ........ ..... .... .... ... 188 
Red Blood Cell Ghost Preparation ..... ........ ........ ............ ........... . 188 




DRUG DELIVERY SYSTEMS: 
In order to increase the targeting specificity and circulation times of 
lipophilic and hydrophilic drugs, we decided to investigate the possibility 
of loading both types of drugs in platelets via the use of liposomes and 
reconstituted Sendai virus envelopes (RSVE). Other techniques for 
loading platelets were available, but for one or more reasons were deemed 
unsuitable. Among these techniques are: microinjection by needles (1,2), 
electroporation (3) and electroinjection (4) and fusion with erythrocyte 
ghosts (5). 
Microinjection has been used to inject a variety of hydrophilic drugs 
into the cytoplasm or the nucleus of living cells . This method is 
reproducible, but the number of cells that can be injected is limited. 
Electroporation techniques, which employ voltage discharges (2-8 kV I em) 
or repetitive pulses of slightly lower field strengths to induce pores in the 
plasma membrane, severely impair cell viability due to cytoplasmic 
leakage (6). Electroinjection, a more recent technique, uses much lower 
field strengths (0.3-0.7 kV I em) to reversibly permeabilize the cell 
membrane (4) . Under carefully defined conditions, electroinjection is an 
efficient and reproducible method for injecting large numbers of cells (106 
cells). As of now, the technique has been applied to loading cultured cells 
with great success; i.e. high loading efficiency and cell viability. However, 
electroinjection of non-cultured cells, including macrophages, has resulted 
in decreased cell function. Fusion of drug-loaded erythrocyte ghosts with 
target cells can be promoted by the addition of polyethylene glycol (5). 
However, the use of an added fusogenic agent complicates this method, 
reduces its efficiency and makes it less specific. 
2 
Loading drugs into cells by the use of liposomes and RSVE can be 
very efficient for cells that are capable of phagocytosis or contain receptors 
which can bind liposomes with specific ligands or RSVE. In addition, 
unlike the microinjection, electroporation or electroinjection methods, 
liposomes or RSVE can load lipophilic as well as hydrophilic drugs into 
cells. 
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The first description of platelets was published in 1824 by Donne, who 
speculated that they might be derivatives from the chyle and perhaps were 
the percursors of leukocytes (1). Forty years later Bizzozero determined 
that platelets were a distinct type of blood cell (2). In 1906 Wright proposed 
that platelets were derived from megakaryocytes (3). 
Megakaryocytes are very large cells, up to 160 ~m diameter, which are 
derived from stem cells within the bone marrow and spleen. Basically 
there are three morphological stages of megakaryocyte maturation prior to 
platelet formation (4). Stage 1, the megakaryoblast, is readily recognized 
by its loose chromatin structure. During this stage the cell enlarges 
progressively with repeated endomitosis and is engaged in extensive 
protein and DNA synthesis. Stage 2, the basophil megakaryocyte, is 
initiated after DNA synthesis and endomitosis are mostly completed. 
During this stage the cell undergoes cytoplasmic maturation, which is 
characterized by intense RNA production and protein synthesis. At the 
commencement of stage 3, the cell is polychromatic but has a nucleus to 
cytoplasm ratio of greater than 1:3. As the cell matures the nucleus 
condenses and the nucleus to cytoplasm ratio falls. In addition the 
remaining basophilia disappear and the granules typical of platelets 
appear. The ratio of organelles to cytoplasm varies greatly with the degree 
of endomitosis. Those with 8N constitution contain a greater ratio of 
organelles to cytoplasm volume; those with 32N constitution contain a 
lesser ratio but a greater membrane content, having undergone more 
5 
extensive endomitosis and membrane synthesis. Presumably this 
heterogeneity accounts for the heterogeneity seen in platelet populations. 
After the completion of stage 3, the bone marrow megakaryocytes, which 
are primarily located within the bone marrow sinusoids (5), adopt an 
amoeboid form with the pseudopodia penetrating through the sinusoidal 
wall into the lumen. The stage of maturation between megakaryocyte 
pseudopodia formation and the earliest circulating platelet remains a 
matter of considerable controversy. It is uncertain whether proplatelet 
projections fragment in the marrow sinusoid to give rise to platelets or 
break off from the parent cell and are carried elsewhere in the circulation 
to undergo subsequent fragmentation. 
Platelet Morphology 
The average human adult has 250,000 platelets/) ... Ll (6) and approximately 
35,000 platelets are produced per microliter of blood every day (7). The 
average lifetime of the platelet is approximately 9-12 days (8). In 
circulation the platelet is a disk shaped cell with an average size of 2-3 ~m 
by 1 ~m; however it can easily change to a spherical or irregular shape b y 
shooting out pseudopodia of various lengths in response to a multitude of 
stimuli. Because the platelet is a cytoplasmic fragment of the 
megakaryocyte, it has no nucleus and the endoplasmic reticulum and 
Golgi complex are virtually absent. 
The ultrastructural features of a platelet are illustrated in Figure 1. 
The anatomy of the platelet can be divided into three major regions: the 
peripheral, the sol-gel and the organelle zones. The peripheral zone is 
composed of the exterior coat, the membrane and the submembrane 
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regions. The exterior coat or glycocalyx covering the outer surface of the 
platelet is approximately 10-20 nm thick and contains various 
glycoproteins important for adhesion and aggregation processes. 
Underneath the exterior coat is the trilaminar unit membrane, 
approximately 7-9 nm thick, which provides a physiochemical separation 
between intracellular and extracellular constituents and processes. The 
core of the membrane is formed by a lipid bilayer to which peripheral 
proteins, such as cytoskeletal proteins, are attached. The lipid bilayer 
contains 70% phospholipid by weight; the remainder consists mainly of 
cholesterol plus a small amount of glycolipids. Five major phospholipid 
classes have been identified in the human platelet (9,10): 
phosphatidylcholine (38%), phosphatidylethanolamine (27%), 
sphingomyelin (19%), phosphatidylserine (10%) and phosphatidylinositol 
(5%). As in red blood cells, the phospholipids are asymmetrically 
distributed over the bilayer. Important components of the plasma unit 
membrane are the Na/K ATPase and the anion pump which help 
maintain the appropriate transmembrane ionic gradients. Another 
characteristic of the membrane is its invaginations which form a network 
of tortuous channels that burrow through the cytoplasm. This system of 
channels, the open channel system (OCS), greatly enhances the surface 
area of the cell and serves as a means for uptake of substances from the 
plasma and rapid extrusion of granule contents into the plasma. 
Intimately associated with the OCS is the dense tubular system (DTS) 
which White has proposed may be derived from the endoplasmic 
reticulum (11). 
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At least three cytoskeletal systems are present in the matrix of the 
platelet: the submembrane filaments, microtubules and microfilaments. 
All of these are believed to contribute in the maintenance of discoid shape 
and extrusion of pseudopodia. 
Electron microscopy reveals several types of organelles in the 
cytoplasm of the platelet including mitochondria and three distinct types 
of granules. Electron dense bodies are distinctive because of their 
intensely opaque internal contents which are often separated from the 
enclosing membrane by a clear space. They are storage sites for ADP, ATP, 
serotonin and calcium (12,13) and number approximately 2-10 per platelet. 
Alpha granules are of moderate electron density, number between 20 to 
200 per platelet and contain fibrinogen (14), factor V (15), von Willebrand 
factor (16,17) and other proteins. The lysosomal granules contain a 
number of acid hydrolases (18). 
Haemostasis 
Haemostasis is the collective noun for the processes that cause 
cessation of the flow of blood through a damaged vessel wall. The main 
components of the haemostatic system are: platelets, humoral coagulation 
enzymes, the layer of endothelial cells that line blood vessels, the 
subendothelial structures, and the smooth muscles that support the 
vessels. 
When a blood vessel is damaged, the defect must be sealed through 
the coordinated action of the components of the haemostatic system. The 
relative contribution of the different components depends on the extent 
and location of the damage. Vasoconstriction may be effective in stopping 
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bleeding in the capillary bed, but is not sufficient in arterioles and venules. 
In these vessels, recruitment of platelets and activation of the coagulation 
system is necessary to achieve haemostasis. Haemostasis in arteries and 
large veins, in which the blood pressure is higher, generally requires 
outside intervention. 
A number of coagulation enzymes circulate in the blood in an 
inactive zymogen form. These zymogens can be converted to their active 
proteolytic forms by cleavage of specific peptide bonds. Damage to the 
endothelium induces adhesion and aggregation of platelets and activation 
of the first enzyme of the coagulation cascade (Figure 2). Successive 
reactions ultimately result in the conversion of soluble fibrinogen into a 
fibrin network. 
Platelet Involvement in Haemostasis: 
The initial reaction to vascular damage is adhesion of platelets to the 
exposed subendothelial structures, which are composed of microfibrils of 
elastin, basement membrane-like amorphous material and collagen fibrils 
(19). Platelet adhesion is largely mediated by a high molecular weight 
protein, von Willebrand factor (20). Under normal physiological 
conditions von Willebrand factor does not readily interact with human 
platelets. However, interactions between von Willebrand factor and the 
subendothelium is thought to produce a conformational change in the 
protein which enables binding to the platelet surface and subsequent 
platelet adhesion. After adhering, platelets often undergo release 
reactions. In the primary release the contents of the dense bodies, which 
include adenine nucleotides and serotonin, are released into the 
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surrounding medium. The release of ADP stimulates new platelets to 
aggregate and serotonin is a mediator of vasoconstriction. Usually a 
second release reaction involving release from the a-granules, which 
contain fibrinogen and factor V, also occurs. Fibrinogen is an essential 
cofactor for platelet aggregation (21,22). Factor V and thrombin activated 
factor V bind to the platelet membrane and serve as a membrane receptor 
for coagulation factor X (23,24). In addition, adherent platelets produce 
metabolites of arachidonic acid, particularly thromboxane A2, a very 
potent platelet-aggregating agent. This close cooperation between platelets 
and clotting factors results in the production of a fibrin-reinforced plug 
localized at the site of the vascular defect. 
Tissue Repair and Fibrinolysis 
As soon as the bleeding is stopped, the tissue repair process begins. 
The fibrin meshwork and cellular debris are removed by fibrinolytic and 
phagocytic processes; healthy cells are stimulated to undergo mitosis. 
Neutrophils and eventually macrophages are attracted to the damaged 
areas by chemotactic factors released during the haemostatic process (25-
27). The phagocytic cells release lytic enzymes and take up cellular debris. 
The fibrinolytic system is activated by a tissue-type plasminogen activator 
released from the endothelium. Fibrinolytic enzymes which enter the 
circulation after resolution of the fibrin meshwork are rapidly inactivated 
by inhibitors present in the blood (28-32). 
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Endothelium Involvement in Haemostasis 
The layer of endothelial cells that line the inner surface of the blood 
vessel is not "inert"; instead it is an active participant in both the 
haemostatic and fibrinolytic processes. After vessel wall injury, the 
stimulated endothelial cells synthesize thromboplastin which initiates the 
coagulation cascade (33,34). In addition, endothelial cells synthesize 
clotting factors V and VIII (35,37). Thrombomodulin, another cofactor 
present on the endothelial cell surface, binds thrombin which increases 
the activation rate of protein C (38,39). Protein C inactivates the 
coagulation factors V3 and VIlla thereby slowing down thrombin 
generation (40-42). Protein C also stimulates the fibrinolytic process 
(43,44). 
Senescence of Platelets 
A large body of evidence supports the idea that platelets undergo a 
process of senescence which results in their removal from the circulation. 
These senescent changes have been related to functional and structural 
parameters. As platelets age they become less adherent to collagen (45), 
less reactive to aggregating and releasing stimuli ( 46), less metabolically 
active (47) and less capable of shortening bleeding times in vivo (48,49). In 
addition, platelets lose sialic acid over time, presumably from surface 
glycoproteins and/ or gangiosides. 
Removal of sialic acid from the platelet surface by neuraminidase 
(50), removal of sialic acid containing glycopeptides by the proteolytic 
enzymes such as plasmin, chymotrypsin and trypsin (51) and alteration of 
sialic acid with sodium periodate (52) have been shown to result in 
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decreased platelet survival in vivo. These findings, in conjunction with 
the observation that platelets lose sialic acid with age, strongly indicate the 
role of desialization in senescent recognition. However, it is not clear by 
what mechanism the RES might recognize desialized platelets. 
Some hypotheses suggest that such cells might be recognized by their 
decreased negative charge. Other data indicate that galactose, the 
penultimate residue of polysaccharide side chains of glycoproteins and 
gangliosides, might be recognized by a membrane receptor . Such a 
receptor has been identified on Kupffer cells (53). Recent findings suggest 
that clearance of desialized erythrocytes is dependent upon a plasma factor 
which possesses many characteristics of an immunoglobulin which may 
recognize a cryptic antigen exposed by desialization (54). The fact that 
desialization, modification of sialic acid and removal of glycopeptides all 
produce decreased platelet survival argues against the galactose receptor 
hypothesis. All of the manipulations reduce negative surface charge and 
could potentially expose cryptic antigens. 
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Figure 1: The ultrastructure of a platelet. MB, microtubule. A, alpha 
granule. L, lysosome. D, dense body. M, mitochondria. OCS, open 
channel system. DTS, dense tubule system. 
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Figure 2: The coagulation cascade. HMWK, high molecular weight 




In the past decade the use of liposomes as potential controlled drug 
delivery systems has gained wide interest (1,2). However, to date, in spite 
of some remarkable successes, the use of liposomes in this capacity has 
been limited. 
Liposomes are microscopic structures consisting of one or more 
concentric lipid bilayers surrounding aqueous compartments. Liposomes 
form spontaneously when amphipathic lipids are dispersed in excess 
water (3). The lipid molecules arrange themselves such that their polar 
heads are towards the water phase and their apolar hydrocarbon 
constituents pack together to form a bilayer. Formation of stable 
liposomes from phospholipids is only possible at temperatures above the 
gel to liquid crystalline phase transition temperature (Tc). The Tc is 
dependent on the nature of the polar head group and the length and 
degree of unsaturation of the acyl chains. Above the Tc, phospholipids are 
in the liquid-crystalline phase which is characterized by an increase in the 
mobility of the acyl chains as compared to that in the gel-phase. 
Multilamellar vesicles (MLV) are formed spontaneously upon 
hydration of dry phospholipid in excess water. These vesicles are very 
heterogeneous in diameter (up to several microns) and shape, but can be 
"sized" by extrusion through polycarbonate filters. Ultrasonication of 
ML V results in a population of significantly smaller (as small as 25 nm) 
homogeneous small unilamellar vesicles (SUV). Large unilamellar 
vesicles (LUV) of most lipid compositions can be prepared b y 
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polycarbonate membrane extrusion or by reverse-phase evaporation as 
described by Szoka et al.(4). The relatively large aqueous volumes of MLV 
and LUV (~3 L/mol of lipid and 6 L/mol of lipid) versus SUV (~0.3 L/mol 
of lipid) make the former liposomes attractive for delivery of hydrophilic 
drugs. However, clearance of liposomes by the reticuloendothelial system 
(RES) is directly proportional to size. 
Liposomes In Vivo 
Three main routes of administration of liposomes exist: 
intravenous, intraperitonial and subcutaneous injection. Although the 
exact values of the circulation half-lives and organ distributions of the 
liposomes vary with the method of administration (5), the majority of 
liposomes are quickly cleared by the RES, especially by macrophages in the 
liver (Kupffer cells) and the spleen (6-8). Circulating monocytes have also 
been reported to take up significant numbers of liposomes (9). In addition 
to size, clearance is also dependent on the liposomes' composition. For 
example, neutral sphingomyelin/ cholesterol vesicles have a circulation 
half-life of approximately 24 hours (10,11) whereas incorporation of a 
phosphatidylserine, a negatively charged lipid, increases the rate of RES 
uptake. The circulation times of liposomes can be improved by the 
addition of polyethylene glycol (PEG) or GM1, a monosialic ganglioside, to 
the liposome formulation (12,13). 
In addition to rapid clearance by the RES, the potential use of 
liposomes as drug delivery systems suffers from the instability of the 
liposomes in serum and the inability of liposomes to target to the desired 
cell types. During circulation within the bloodstream, liposomes may be 
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susceptible to the destabilizing effects of serum proteins and 
phospholipases, resulting in leakage of their encapsulated water-soluble 
compounds. High density lipoproteins (HDL) have been shown to 
penetrate the liposomal bilayer and induce leakage (14,15). This can be 
overcome to some extent by the addition of cholesterol, which improves 
retention by impeding penetration of the serum proteins (16). Targeting of 
liposomes to cells other than those in the RES and the blood has also 
presented several problems. This is primarily because the vesicles must 
first cross the capillary endothelium and the basement membrane and 
many cell types, including most tumor cells, display only very low 
endocytic capacities. Techniques to improve the targeting ability of 
liposomes include the addition of cell specific antibodies to the surface of 
the liposomes. However, use of these liposomes has met with limited 
success since they are still prone to RES uptake (17). 
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Sendai virus is a murine parainfluenza virus belonging to the genus 
Paramyxovirus, family Paramyxoviridae (1). Sendai virus particles are 
pleomorphic and range in size from 150 to 250 nm. The virions are bound 
by a lipid bilayer membrane which contains two surface glycoproteins, 
hemagglutinin-neuraminidase (HN) and fusion (F) w hich are anchored in 
the plasma membrane by h ydrophobic transmembrane domains (2,3). The 
HN protein (Mr = 64000) is responsible for viral attachment and binds to 
cells via sialic acid containing receptors; predominantly gangliosides (4). 
HN also has hemagglutinin and neuraminidase activities, the clumping 
and aggregation of red blood cells and enzymatic cleavage of sialic acid, 
respectively. The F protein (Mr = 53000) penetrates the host cell and 
induces fusion. 
In addition to the two surface glycoproteins, Sendai virus contains 
matrix protein (M), nucleocapsid protein (NP), and L and P proteins 
(Figure 1). M protein (Mr = 39500), a viral envelope protein, is thought to 
function in maturation and assembly of the virions in infected cells (5). 
NP, L and P are nucleocapsid proteins. NP (Mr = 57800) is the structural 
protein of the nucleocapsid and may play a role in packaging 
nucleocapsids into maturing virions (6,7). L (Mr = 255800) and P (Mr = 
67500) appear to act cooperatively in viral RNA synthesis as well as in 
other enzymatic functions of the nucleocapsid including methylation, 
capping and polyadenylation of mRNA (6) . 
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Reconstituted Sendai Virus Envelopes 
Fusogenic reconstituted viral envelopes can be obtained by 
solubilization of the virus with Triton X-100 (8). Following addition of the 
detergent, the solubilized membrane is separated from the insoluble 
nucleocapsid by centrifugation. The remaining detergent is removed by 
dialysis or the addition of SM-2 Biobeads (8). Addition of aqueous 
compounds to the detergent solubilized-viral mixture results in their 
entrapment within the vesicles formed after the removal of the detergent. 
Lipophilic compounds added to the detergent-solbilized mixture are 
integrated into the reconstituted viral envelope. Subsequently, fusion of 
the RSVE with cells results in the injection of aqueous compounds into 
the cytoplasm and lipophilic compounds into the cells' plasma 
membranes (Figure 2). Compounds that have been successfully entrapped 
in RSVE and injected into cells include ferritin (9), 3H-IgG (10) and DNA 
(9). 
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Figure 1: The ultrastructure of Sendai virus. NP, nucleocapsid protein. L, 
large protein. P, polymerase protein. M, matrix protein. F, fusion protein. 












































































































































































Figure 2: A model of the fusion of a reconstituted Sendai virus envelope 
with a cell membrane and the injection of incorported membrane proteins 




PHAGOCYTOSIS OF LIPOSOMES BY HUMAN PLATELETS 
R. Male, W. E. Vannier and J. D. Baldeschwieler 
ABSTRACT 
We have shown that platelets are capable of phagocytosing liposomes 
rather than simply sequestering particles as previously postulated. 
Incubation of human platelets with small neutral unilamellar liposomes, ~ 74 
nm, resulted in the uptake of the liposomes and retention of the lipid with 
rapid release of the aqueous phase components. The lipid label 3H-
cholesterylhexadecyl ether and water soluble 3H-inulin were used to study 
the fate of the liposome components. Uptake of liposomes was proportional 
to the number of liposomes added and to the incubation time. 
Approximately 250 liposomes per platelet were taken up within a five hour 
incubation period. Uptake of the liposomes occurred through the open 
channel system, as evidenced by thin section electron microscopy, and was 
followed by accumulation and degradation in acid and esterase containing 
vesicles, as determined by changes in fluorescence of the pH-sensitive probe, 
pyranine (1-hydroxypyrene-3,6,8-trisulfonic acid), and hydrolysis of the 
cholesteryl[14C]oleate membrane marker. Uptake was inhibited by the 
addition of EDTA, cytochalasin B or 2,4 dinitrophenol and iodoacetate to the 
media. Results from the serotonin release assay, microaggregation assay, 
fluorescein diacetate membrane integrity assay and electron microscopy 
indicate that neither the conditions for loading nor phagocytosis of liposomes 
significantly alters platelet function or morphology. 
INTRODUCTION 
Platelets have been shown to take up a variety of particles in vitro (1-6), 
and evidence is accumulating which suggests that removal of foreign 
materials from the blood may be an important physiologic role for these cells 
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(7-10). However, it remains to be definitively demonstrated whether platelets 
are truely phagocytic or simply sequester the particles within the open 
channel system. 
In prior work, the platelet-latex sphere system has been used as a model 
for foreign particle ingestion by these cells (2,3,11-13). Various studies have 
shown progressive accumulation of latex spheres in the open channel system 
(OCS), a system of channels believed to be formed by invagination of the 
plasma membrane. Lewis et al. noted subsequent localization of the particles 
in acid phosphatase-positive electron-opaque vacuoles and concluded that 
platelets phagocytose latex particles (13). However, White et al. concluded 
that platelets sequester latex particles within membrane invaginations which 
are in communication with the exterior of the cell (12). We report the use of 
small neutral unilamellar liposomes to study the possible phagocytosis of 
particles by platelets. Liposomes have been used extensively to model 
microorganism interactions and, unlike latex beads, are more suitable for the 
study of uptake, metabolism and exocytosis. 
MATERIALS AND METHODS 
Purification of Platelets. Platelets were prepared using two methods; 
experiments measuring uptake using either platelet preparation gave similar 
results. Platelet-rich plasma packs obtained from the Red Cross were diluted 
in a 1:1 ratio with 0.9% saline solution. A volume of 4.5% dextran (molecular 
weight 250,000) in saline solution was added to an equal volume of the 
diluted packs and stirred; the red blood cells were allowed to sediment for 30 
minutes at room temperature. Fifteen ml aliquots of the supernatant were 
pipetted into centrifuge tubes. Equal volumes of a solution containing 6.35% 
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Ficoll and 10% Hypaque w /w were gently layered on the bottom of the tubes. 
The tubes were spun at 400 g for 15 minutes at room temperature. The 
cloudy band containing the platelets and lymphocytes located directly above 
the Ficoll-Hypaque gradient was gently removed, diluted in a 1:1 ratio with 
saline solution and centrifuged at 300 g for 15 minutes at room temperature to 
sediment the lymphocytes. The supernatant was spun at 800 g for 20 
minutes; the platelet pellet formed was washed twice in saline solution and 
finally resuspended in Hanks' Balanced Salt Solution (HBSS). 
Platelets purchased from the American Blood Institute (Los Angeles) 
were centrifuged at 1000 g for 15 minutes in an IEC Centra-8 centrifuge. The 
pellet was resuspended in either 0.9% saline solution or Tyrodes buffer and 
spun at 110 g for 5 minutes to remove excess red blood cells. The supernatant 
was spun at 450 g for 10 minutes. The pellet was resuspended in HBSS or 
modified Tyrodes buffer (Tyrodes buffer plus 1.26 mM of CaCb). 
The final purities of both platelet preparations were greater than 95% 
platelets as assessed by a Colter S+4 Cell Counter; the main contaminants 
were red blood cells. Platelets were used within 24 hours of blood collection. 
Determination of the Number of Platelets per mg of Protein. Cell 
counts were performed with a Colter S+4 Cell Counter to determine the 
number of platelets. The Peterson modification of the Lowry protein assay 
(14) with a bovine serum albumin standard and without TCA precipitation 
was used to determine the amounts of protein in the same samples. A 
milligram of protein was found to correspond to 3 x 108 platelets. 
Preparation of the Liposomes. 3H-cholesterylhexadecyl ether Labeled 
Liposomes: A 2:1 mole ratio mixture of distearoylphosphatidylcholine (Avanti 
Polar-Lipids, Inc.) and cholesterol (cell culture tested Sigma Chemical Co.) in 
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chloroform was made such that the total lipid content was approximately 20 
mg. Five f...LCi of 3H-cholesterylhexadecyl ether (New England Nuclear) in 
chloroform was also added. The solution was then taken to dryness in a 100 
ml round bottom flask with a Buchler "Rotovap" apparatus and was dried 
under vacuum overnight. The resulting phospholipid mixture was 
resuspended in 5 mL of PBS (0.90% NaCl: 0.12% Na2HP04·?H20: 0.013% 
NaH2P04·H20 w /w in water, pH 7.3), vortexed and 2.5 ml portions probe 
sonicated for 15 minutes using a Heat Systems-Ultrasonics, Inc. sonicator 
with a microprobe. 
3H-inulin Labeled Liposomes. The liposomes were prepared exactly as 
described except that no 3H-cholesterylhexadecyl ether was added and the 
resuspension buffer contained 5 f...LCi of 3H-inulin (Amersham, Corp.). Excess 
3H-inulin, (molecular weight 5,200) was separated from the liposomes by gel 
filtration with a Sephadex G-50-100 column. 
Non-radiolabeled Liposomes. The liposomes were prepared as described but 
without the tritiated labels. 
Pyranine (1-hydroxypyrene-3,6,8-trisulfonic acid, HPTS) Labeled Liposomes. 
The liposomes were prepared as described above except that the 
resuspension solution was 35 mM in HPTS (Molecular Probes) and 75 mM in 
NaCl. Excess HPTS was removed by gel filtration with a Sephadex G-50-100 
column equilibrated with 150 rnM NaCl. 
Cholesteryl[14C]oleate Labeled Liposomes. The liposomes were prepared as 
described for the 3H-cholesterylhexadecyl ether labeled liposomes except 5 
f...LCi of cholesteryl[14C]oleate (Amersham, Corp.) in chloroform was added 
instead of 3H-cholesterylhexadecyl ether. 
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Incubation Procedure. The platelets and liposomes were incubated at 
37°C in 1.5 mL polypropylene centrifuge tubes for the desired incubation 
times after which the mixtures were centrifuged at 5700 g for 5 minutes in a 
Beckman Microfuge 11. The pellets were washed twice in buffer and finally 
resuspended in 0.5 M NaOH/0.5% SDS and incubated overnight at room 
temperature. The solution was transferred to liquid scintillation vials with 10 
ml of Safety Solve (Research Products, Inc.), mixed and allowed to sit at least 
two hours prior to scintillation counting. For each experiment all samples 
were done in duplicate; the number of independent experiments, n, are noted 
in the figure captions or in the text. Bars on the graphs represent the range of 
the data. 
Exocytosis Studies. Platelets and liposomes were incubated as above for 
12 hours. The mixtures were centrifuged and the platelets washed by 
centrifugation twice in buffer to remove excess liposomes and further 
incubated at 37oc for varying periods of time. Both the pellets and 
supernatants were collected by centrifugation, solubilized in the NaOH/SDS 
solution overnight and counted. 
Determination of Liposome Diameters and Estimation of Liposome 
Numbers . The liposome diameters for different preparations were 
determined by photon correlation spectroscopy at 480 nm using a Malvern 
Instruments PCS 100 system. The numbers of 3H-cholesterylhexadecyl ether 
labeled liposomes were calculated by assuming that the counts per weight of 
lipid were constant for all preparations, the average surface area for a 
phospholipid molecule is 0.7 nm2 (15) and the average molecular weight for 
the lipid is 656 g/mole. The numbers of 3H-inulin labeled and non-
radiolabeled liposomes were determined by performing Bottcher phosphate 
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assays (16) on the samples and assuming a 0.7 nm2 phospholipid surface area. 
The light scattering data indicated that the liposomes diameters were 65 to 83 
nm. The number of liposomes reported have all been normalized assuming 
that the diameters of the liposomes for all experiments were 74 nm. 
Fluorimetry of HPTS. After incubation with HPTS labeled liposomes for 
various times, the cells were washed twice with buffer. Fluorescence 
excitation spectra (Aex 395-465 nm, 4 nm bandwidth) were measured at 510 
nm emission (4 nm bandwidth) using a SLM 4800 (SLM Instruments, Inc.) 
outfitted with a stirred, temperature controlled cuvette (2QOC). HPTS is a 
pH-dependent dye which exhibits two major fluorescence maxima (403 and 
460 nm) which have a complementary pH dependence in the range 5-9; the 
peak at 403 nm is maximal at low pH values while the peak at 460 nm is 
maximal at high pH values. The fluorescence at 413 nm is relatively pH-
independent and is used to standardize the concentration of dye associated 
with the cells. The fraction of liposomes taken up by phagocytosis and 
delivered to an acidic, pH 6.0, environment was calculated using the 460/413 
nm ratio and the equation: 
Fraction phagocytosed = (ratiO pH 7.4 -ratiorneas.)/ (ratiOpH 7.4-ratiopH 6.0) 
where ratiOrneas. is the 460/413 ratio of the liposome treated cells and ratiopH 
7.4 and ratiopH 6.0 are the 460 I 413 ratios of liposomes in buffer and acidified 
buffer respectively (17). In the original paper by Daleke et al., the second peak 
occurred at 450 nm; however, according to our data the peak maximum is at 
460nm. 
Intralysosomal Degradation of the Cholestery1[14C]oleate Labeled 
Liposomes. 3 x 108 Platelets were preincubated with 7 x 1011 of 3H-
cholesterylhexadecyl ether or cholesteryl[14C]oleate labeled liposomes for 0.5 
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hour at 370C. The mixtures were washed twice in buffer by centrifugation. 
The pellets were collected, resuspended in buffer and incubated for 10 to 60 
minutes at 37°C. Following incubation, the mixtures were centrifuged to 
collect the pellets that were then solubilized in NaOH/SDS solution 
overnight and counted. 
Upon intralysosomal degradation cholesteryl[14C]oleate is hydrolysed to 
form [14C]oleate which is released from cells. Conversely, 3H-
cholesterylhexadecyl ether is retained within the cells. Therefore, by 
monitoring the 3Hj14C ratio of the pellets, the degree of degradation can be 
determined (18). 
Thin Section Electron Microscopy. Samples of 3 x 108 platelets were 
incubated with 7 x 1011 non-radiolabeled liposomes for 6 hours at 370C, fixed 
in standard fashion and embedded in LR white. 
In addition, platelets suspended in HBSS or modified Tyrodes buffer 
incubated with or without liposomes for 1 hour at 37°C, prepared as above, 
were studied to determine changes in platelet morphology under the 
conditions used for studying the liposome interaction. 
In vitro Studies to Assess Platelet Function. Serotonin Release Assay. The 
serotonin assay was performed with 3 x 108 platelets, suspended in HBSS or 
modified Tyrodes and incubated with or without 1.4 x 1Q12liposomes for one 
to nine hours, as described (19). 
Microaggregation Assay. Platelets suspended in HBSS or modified Tyrodes 
solution were incubated at 37°C, with or without liposomes, for one to nine 
hours and then fixed with 1% glutaraldehyde. The percentages of aggregated 
platelets were determined by examining the cells in a hemacytometer. 
40 
Fluorescein Diacetate Assay. After incubation of platelets suspended in 
HBSS or modified Tyrodes solution at 37oc, with or without liposomes, for 
one to nine hours, fluorescein diacetate (Sigma Chemical Co.) was added and 
incubated (final concentration 4Jlg/mL) with the cells for 10 minutes at room 
temperature. The platelets were then kept on ice for 1 minute and pelleted at 
4oc. The fluorescence was measured at 520 nm emission while exciting at 489 
nm. 
FDA is a non-fluorescent probe which readily crosses the cell membrane. 
Within the cell the probe is hydrolysed by esterases to form fluorescent 
fluorescein which does not readily traverse the cell membrane at 4°C but can 
leak out of the cells through membrane lesions. Therefore the leakage of 
fluorescein is a measure of loss of membrane integrity (20). 
RESULTS 
3H-cholesterylhexadecyl ether Labeled Liposome Uptake. In order to 
model the liposome uptake by platelets, 3H-cholesterylhexadecyl ether 
labeled liposome uptake was studied for varying incubation times and 
incubation concentrations of both the liposomes and platelets. Platelet uptake 
of 3H-cholesterylhexadecyl ether labeled liposomes increased with increasing 
incubation times (Fig. 1). After incubation of 3 x 108 platelets with 7 x 1011 
liposomes for five hours, approximately 250 liposomes were associated with 
each platelet. Liposome uptake by platelets also increased with increasing 
numbers of incubated liposomes; two incubation times are shown (Fig. 2). 
Incubation for 12.5 hours resulted in greater uptake values than the 2.0 hour 
incubation. As the number of platelets incubated with a constant amount of 
liposomes was increased, the overall number of liposomes incorporated 
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increased; however the ratio of liposomes to platelets remained constant at 
approximately 475 liposomes/platelet for a 12.0 hour incubation period (Fig. 
3). 
3H-inulin Labeled Liposome Uptake. Uptake of the aqueous 
components of the liposomes was studied by following the uptake of 3H-
inulin labeled liposomes versus varying incubation times and liposome 
concentrations. Although the number of 3H-inulin labeled liposomes taken 
up increased with time (Fig. 4), the kinetics of uptake were different than that 
for the 3H-cholesterylhexadecyl ether labeled liposomes. Incubation of 
2 x 1012 liposomes with 3 x 108 platelets resulted in the uptake of 
approximately 150 liposomes per platelet after five hours. The uptake of 3H-
inulin labeled liposomes versus the concentration of liposomes incubated is 
shown for two different incubation times (Fig. 5). Uptake was proportional 
to both the number of liposomes incubated and the incubation time. The 
difference in kinetics of uptake as assessed by the lipid label and the aqueous 
label suggests that there is a difference in the fate of the lipid and aqueous 
components after platelet uptake. Therefore the values reported for the 
uptake of the 3H-inulin labeled liposomes are given as "apparent liposomes 
per platelet". 
Release of the Tritiated Radiolabels. To study the possible exocytosis of 
the liposomes, the amounts released of the tritiated radiolabels, 3H-
cholesterylhexadecyl ether and 3H-inulin probes were examined (Fig. 6). 
After 12 hours no membrane associated probe was released. However, up to 
60% of the aqueous phase probe was released during this period. 
HPTS Labeled Liposome Uptake. In order to determine the percentage of 
liposomes phagocytosed and delivered to acidic compartments, the uptake of 
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fluorescently labeled (HPTS) liposomes was measured by fluorimetry versus 
time (Fig. 7). Initially the liposomes were associated with the platelets, either 
bound to the surface or contained in the OCS, but were not phagocytosed. 
Within minutes the liposomes began to accumulate in acid-containing 
vesicles. The percentage of platelet associated liposomes phagocytosed 
increased to 80% within one hour. 
Cholesteryl[14C]oleate Labeled Liposome Degradation. Liposome 
degradation was monitored by studying the time dependence of the relative 
abundances of 3H and 14C within the platelets after preincubating the cells 
with 3H-cholesterylhexadecyl ether or cholesteryl[14C]oleate labeled 
liposomes for half an hour, washing the pellets twice and resuspending in 
buffer (n=10). During a sixty minute time period, the 3Hj14C ratios within 
the cells increased linearly from 1.00 at 0 min., 1.028 at 10 min., 1.130 at 20 
min., 1.212 at 30 min, 1.246 at 50 min. to 1.294 at 60 min. 3H-
cholesterylhexadecyl ether was retained within the platelets; however the 
cholesteryl[14C]oleate was hydrolysed to form [14C]oleate which was 
released by the cells. Therefore the increase in the 3Hj14C ratio in the cells 
was indicative of degradation of the liposomes. The amount of liposome 
degradation is probably underestimated since the incubations were done in 
the absence of serum which is unfavorable for the release of oleate (21). 
Electron Microscopy. Electron microscopy was performed to study the 
effects of HBSS and modified Tyrodes solution and the phagocytosis of 
liposomes on platelet morphology (n=4). The effects of incubation of up to 
2.1 x 1Q121iposomes were studied. 
Platelets maintained a discoid shape when suspended in modified 
Tyrodes buffer. However, platelets suspended in HBSS tended to have 
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irregular shapes and approximately half had pseudopodia. Therefore we 
believe that incubation in modified Tyrodes buffer is superior. Incubation 
with liposomes did not significantly alter platelet morphology. 
Competitive Assay. A competitive assay was performed to establish 
whether liposome uptake could be saturated. Preincubation of platelets with 
0 to 3.4 x 1012 non-radiolabeled liposomes prior to two centrifugation washes 
and incubation with 7.9 x 1011 tritiated liposomes for preincubation times of 
0.5, 2 and 6 hours and incubation times of 0.17, 0.5, 2 and 6 hours gave 
similar results (data not shown, n=4) The amount of 3H-cholesterylhexadecyl 
ether liposomes taken up was independent of the amount of non-radiolabeled 
liposomes previously added. In addition, uptake was relatively independent 
of the preincubation time while uptake increased with increasing incubation 
times. Simultaneous incubation of non-radiolabeled and 3H-labeled 
liposomes resulted in a linear decrease in uptake of the 3H-labeled liposomes 
as expected. 
Inhibition of Liposome Uptake. The inhibitory effects of a variety of 
reagents known to decrease platelet uptake of latex spheres were examined 
during platelet incubation with liposomes. Incubation for 12 hours in the 
presence of 5mM EDTA inhibited the uptake of liposomes by 48±9%; 
however, incubation for 1 hour showed no significant inhibition of uptake 
(n=lO). The addition of 10 IJ.g/ml of cytochalasin B (n=8) or 2.5 
x lQ-4 M 2,4-dinitrophenol with 5 x 10-s M iodoacetate (n=8) also inhibited 
uptake by 46±16% and 66±12% respectively. 
In vitro Assays to Assess Platelet Function. Although the numbers of 
liposomes phagocytosed by platelets suspended in HBSS or modified Tyrodes 
buffer are identical, the in vitro assays showed that platelets, incubated with 
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or without liposomes, spontaneously secrete serotonin, aggregate and lose 
membrane integrity more while suspended in HBSS. However, phagocytosis 
of liposomes did not significantly alter platelet secretion of serotonin or 
induce additional platelet aggregation or loss of membrane integrity. This 
was not surprising since it had been previously shown that the uptake of 
"Intralipid", a lipid emulsion used in treatment of patients with deficient 
caloric intake, does not increase platelet aggregation or induce morphological 
changes (22). 
DISCUSSION 
We have determined that platelets are capable of phagocytosing small 
unilamellar liposomes rather than sequestering particles as previously 
postulated (12). Liposomes are taken up through the OCS, localize within 
acid and esterase containing vesicles and are degraded. The lipid is retained; 
the aqueous components are exocytosed. Therefore all uptake values 
reported using 3H-inulin labeled liposomes really reflect a consecutive first 
order kinetic scheme of uptake and exocytosis. 
The values reported in this paper for platelet uptake do not differentiate 
between incorporated and bound liposomes. However, according to EM 
micrographs, the vast majority of the liposomes appear to be within the OCS. 
In addition the use of a pH-dependent fluorescent liposome probe confirms 
that a substantial portion of the liposomes are phagocytosed and are in acid-
containing compartments. These data suggest that the liposomes are 
incorporated in surface invaginations which pinch off their connections to the 
cell membrane and migrate into the cytoplasm as sealed vesicles, rather than 
being sequestered in the OCS and in contact with the outside media. 
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Degradation of the liposomes, which probably occurs in the acid-phosphatase 
and esterase containing vacuoles, has also been demonstrated by utilizing 
cholesteryl[14C]oleate labeled liposomes. The mechanism for the release of 
the aqueous components to the outside of the cell probably involves the 
migration of these vacuoles to the periphery of the cell and exocytosis of their 
contents; however, this has not been confirmed. 
Although the space available for uptake within the cell must be limited, 
the exocytosis of the aqueous components of the liposomes increases the 
amount of liposome lipid capable of being stored as detected by the 3H-
cholesterylhexadecyl ether label. With the amounts of liposomes and 
platelets used and on the time scale of the preincubation experiments, the 
space available for uptake is not saturable. The uptake is independent of the 
amount of non-radiolabeled liposomes added and the preincubation times. 
Simultaneous incubation of non-radiolabeled and radiolabeled liposomes 
demonstrates a dilution effect, which results in decreased uptake of the 
radiolabeled liposomes. 
According to Mustard et al. the addition of EDTA inhibits phagocytosis of 
particles and platelet aggregation, but does not interfere with particle 
adherence (3). Liposome uptake is inhibited by the presence of EDTA at long 
time intervals but not at short intervals when the predominant process of 
uptake in the absence of Ca2+ may be binding. This evidence suggests that 
divalent cations are involved in the phagocytosis process; however, the effects 
of different divalent cations have not been investigated. The inhibitory effect 
of cytochalasin B with respect to platelet uptake has been attributed to its 
effect on microfilaments and the plasticity of the platelet membrane (23). The 
addition of 2,4-dinitrophenol and iodoacetate prior to incubation blocks 
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aggregation and phagocytosis by interfering with glycolysis and oxidative 
phosphorylation (2). Liposome uptake is Ca2+ dependent; however, platelets 
tend to aggregate and secrete more in the presence of Ca2+. Therefore we 
studied the effects of HBSS and modified Tyrodes buffer on the morphology 
and function of platelets which both contain 1.26 mM CaCl2. The serotonin 
release assay, microaggregation assay and FDA membrane integrity assay all 
show that platelet function and morphology are better preserved in modified 
Tyrodes than in HBSS. However, even in modified Tyrodes buffer, the loss of 
membrane integrity is significant. This loss may be due to incubation of the 
platelets in small polypropylene centrifuge tubes at 37oc. It is preferable to 
store platelets at room temperature, but phagocytosis is maximized at 37oc. 
The assays also indicated that phagocytosis of liposomes does not adversely 
affect the platelets. 
Although we began this research to define the mechanisms involved in 
platelet-liposome interactions, we realize the ability to encapsulate a variety 
of drugs or radioactive labels in vitro in platelets and to target specific 
locations in vivo such as areas of inflammation or infection, neoplastic tumor 
cells or thrombosis would be of great medical importance. The exocytosis 
process is comparatively rapid, the half life of the aqueous compartment 
calculated assuming a first order reaction is 3.9 hours, therefore it may be 
necessary to use inhibitors which would slow the digestion of the liposomes 
or the release of the liposomes' aqueous components. Alternatively, lipid 
analogs of the drugs could be used for longer platelet retention. In some 
cases rapid release of drugs from the aqueous compartments may be 
desirable. An example of this might be the delivery of thrombolytic agents to 
a coronary thrombus in the initial treatment of myocardial infarction. 
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Figure 1: Incubation time dependence of platelet uptake of 3H-
cholesterylhexadecyl ether labeled liposomes. 3 x 108 platelets were 
incubated with 7 x 1011 3H-cholesterylhexadecyl ether labeled liposomes at 
37oc for varying incubation times (n=8). 
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Figure 2: Liposome concentration dependence of platelet uptake of 3H-
cholesterylhexadecyl ether labeled liposomes. 3 x 108 platelets were 
incubated with varying amounts of 3H-cholesterylhexadecyl ether labeled 
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Figure 3: Platelet concentration dependence of platelet uptake of 3H-
cholesterylhexadecyl ether labeled liposomes. 8.3 x 1011 3H-
cholesterylhexadecyl ether labeled liposomes were incubated with varying 
numbers of platelets (0.5 mL final volume) at 37°C for 2.0 hours. The line 






















Figure 4: Incubation time dependence of platelet uptake of 3H-inulin labeled 
liposomes. 3 x 108 platelets were incubated with 2 x 1012 3H-inulin labeled 
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Figure 5: Liposorne concentration dependence of platelet uptake of 3H-inulin 
labeled liposornes. 3 x 108 platelets were incubated with varying amounts of 













































Figure 6: Release studies of the lipid and aqueous probes. 3 x 108 platelets 
were preincubated with 8.3 x 1011 3H-cholesterylhexadecyl ether labeled (e) 
or 2 x 1012 3H-inulin labeled (0) liposomes at 37oc for 12.0 hours. The cells 
were then pelleted, washed twice in buffer, resuspended in buffer and 
incubated for various incubation times at 37°C. The percents of the 3H-























Figure 7: Incubation time dependence of the percentage of platelet associated 
HPTS labeled liposomes phagocytosed. 3 x 108 platelets were incubated with 
7 x 1011 HPTS labeled liposomes at 37oc for varying incubation times. The 
cells were then pelleted, washed twice in buffer and resuspended in buffer. 





KINETICS OF LIPOSOME UPTAKE BY HUMAN PLATELETS 
R. Male, W. E. Vannier, J.D. Baldeschwieler 
ABSTRACT 
Distearoylphoshatidylcholine:cholesterol (2:1 mole ratio) small unilmallar 
vesicles are taken up intact by human platelets with a rate constant of k1 = 7.1 
x 1Q-3 hr1 M-1. The lipid is retained; the aqueous components are exocytosed 
with a rate constant of k2 = 1.8 x 10-1 sec-1. 
INTRODUCTION 
The uptake of 3H-cholesterylhexadecyl ether labeled (lipid label) and 3H-
inulin labeled (aqueous-phase label) DSPC:cholesterol (2:1 mole ratio) 
liposomes by human platelets was studied (see Chapter 2). Uptake of both 
types of liposomes was linear with time and liposome incubation 
concentration. However, uptake of the 3H-cholesterylhexadecyl ether labeled 
liposomes was greater than that of the 3H-inulin labeled liposomes. These 
data suggested that the intracellular fates of the lipid and aqueous 
components might be different. Therefore the uptake of pyranine labeled 
and cholesteryl[14C]oleate labeled liposomes was examined to detect possible 
lysosomal uptake and degradation of the liposomes. Pyranine is a pH-
dependent dye that exhibits two major fluorescence maxima, which have a 
complementary pH dependence in the range pH=S-9 (1) . Upon 
intralysosomal degradation, cholesteryl[14C]oleate is hydrolyzed to form 
[14C]oleate, which is released from cells (2). From these data it was apparent 
that the liposomes were taken into acid-containing vacuoles and degraded. 
The presence of 3H-inulin in the supernatant following preincubation of 3H-
inulin labeled liposomes with platelets, removal of free liposomes by 
centrifugation, resuspension in buffer and incubation confirmed that the 
aqueous components were exocytosed. Similar studies with 3H-
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cholesterylhexadecyl ether labeled liposomes demonstrated that the lipid is 
retained. The overall mechanism of DSPC:cholesterol (2:1 mole ratio) 
liposome uptake by platelets is summarized in Figure 1. The kinetics of 
uptake of DSPC:cholesterol (2:1 mole ratio) liposomes and exocytosis of the 
aqueous components, based on the data presented in Chapter 2, is discussed. 
MATERIALS AND METHODS 
The methods for preparation of the liposomes and platelet preparation 
are given in Chapter 2. 
RESULTS 
Uptake of 3H-cholesterylhexadecyl ether labeled liposomes. Platelet 
uptake of 3H-cholesterylhexadecyl ether labeled liposomes increased w ith 
increasing incubation time (Figure 2). In addition, the amount of uptake was 
independent of the number of non-radiolabeled liposomes preincubated with 
the platelets prior to the addition of the radiolabeled liposomes and the 
preincubation time (data not shown) . Therefore the uptake of the 3H-
cholesterylhexadecyl ether labeled liposomes can be modeled as follows: 
LiposomeSfree +Platelets ~ Liposomesphagocytosed 
d[phagocytosed] k [f ] -=...__=---=----=- = 1 ree 
dt 
[phagocytosed] = k1[free]t; where [free]~ 7 x 10llliposomes/0.5 ml. 
The number of 3H-cholesterylhexadecyl ether labeled liposomes 
phagocytosed, as compared to the number added, is less than 10%, therefore 
the number of free liposomes is approximately constant. Since platelet uptake 
is independent of the amount of previously phagocytosed liposomes, the 
67 
platelet reaction sites are represented as part of the constant k1. Using this 
model and the data in Figure 2, k1 is determined to be 7.1 x 1Q-3 hrl M-1. 
3H-inulin labeled liposome exocytosis. To study the possible exocytosis of 
the liposomes, the amounts released of the tritiated radiolabels 3H-
cholesterylhexadecyl ether and 3H-inulin following preincubation of the 3H-
labeled liposomes with platelets, removal of free liposomes by centrifugation, 
resuspension in buffer and incubation were examined (Figure 3). After 12 
hours no membrane-associated probe was released. However, up to 60% of 
the aqueous-phase probe was released during this period. The release 
kinetics are modeled as shown below. 
Liposomephagocytosed => 3H-inulinfree 
d[phagocytosed] k [ h d] 
---=..:'----=----"-----=- = - 2 p agocytose 
dt 
In( [phagocytosed] = -k2t 
[phagocytosed]o 
Using this model and the data in Figure 3, k2 is determined to be 1.8x1Q-lhr-1. 
Uptake of 3H-inulin labeled liposomes. DSPC:cholesterol (2:1 mole ratio) 
liposomes are phagocytosed intact; however, the intracellular fate of the lipid 
and the aqueous components are different. The exocytosis of the 3H-inulin 
label after liposome degradation, is reflected in the apparent decrease in the 
uptake values for the 3H-inulin labeled liposomes. Therefore the values 
reported for the uptake of the 3H-inulin labeled liposomes are given as 
"apparent liposomes per platelet". The model below describes the kinetics of 
the platelet associated 3H-inulin probe which is dependent on both the 
uptake of the 3H-inulin labeled liposomes and the exocytosis of the free 
probe. 
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LiposomeSfree +Platelets=> Liposomesphagocytosed => 3H-inulintree 
[phagocytosed] k1 
-=-----=-~-____;;. = {exp(-klt)- exp( -kzt)} 
[free]o (kz- k1) 
Figure 4 shows the uptake of 3H-inulin labeled liposomes. The curve is 
derived from the above equation using the values of k1 and k2. 
DISCUSSION 
The uptake of DSPC:cholesterol (2:1 mole ratio) liposomes occurs through 
the OCS and the lysosomal pathway. The liposomes are taken up intact with 
an uptake rate of k1 = 7.1 x 1Q-3 hr-1 M-1 and are then degraded, presumably 
in the acid-containing vacuoles. The lipid is retained; the aqueous 
components are exocytosed. The exocytosis also appears to follow a first 
order reaction scheme with k2 = 1.8 x lQ-1 hr. 
The potential of using liposome-loaded platelets as a new drug delivery 
system relies greatly on the kinetics of uptake and exocytosis of the 
liposomes. Lipophilic drugs introduced into platelets by this method will 
remain within the cell indefinitely. Therefore, liposome-loaded platelets, 
which contain lipophilic diagnostic drugs, might be ideal for imaging platelet 
rich tumors or clots. Aqueous drugs will be exocytosed from the platelets 
with a half-life of 4 hours. Therefore, aqueous drugs, which are insensitive to 
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Figure 1: A schematic representation of the uptake of DSPC:cholesterol (2:1 
mole ratio) liposomes by human platelets. 
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Figure 2: Incubation time dependence of platelet uptake of 3H-
cholesterylhexadecyl ether liposomes. Platelets (3 x 108) were incubated with 
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Figure 3: Release studies of lipid and aqueous probes. Platelets (3 x 108) were 
preincubated with 8.3 x 1Q113H-cholesterylhexadecyl ether liposomes (e) or 2 
x 1012 3H-inulin labeled liposomes (0) at 37°C for 12 hours. Cells were then 
pelleted, resuspended in buffer, and incubated for various incubation times at 
37°C. Percentages of the 3H-cholesterylhexadecyl ether and 3H-inulin labels 
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Figure 4: Incubation time dependence of platelet uptake of 3H-inulin labeled 
liposomes. Platelets (3 x 108) were incubated with 2 x 1Q121iposomes at 37°C 
for various incubation times. 
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CHAPTER FOUR 
ORGAN DISTRIBUTIONS OF LIPOSOME-LOADED RAT 
PLATELETS 
R. Male, D. G. Moont, J. S. Gatvey, W. E. Vannier, and J. D. Baldeschwieler 
Department of Chemistry, California Institute of Technology 
tAlbany College of Pharmacy, Albany, New York 
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ABSTRACT 
Past in vitro functional assays have demonstrated that platelet 
function is not inhibited by liposome uptake. In the present study, the 
organ distributions of control and liposome-loaded Sprague-Dawley rat 
platelets were examined to determine whether liposome uptake enhances 
reticuloendothelial system (RES) uptake. Platelets were isolated using 
STRactan density gradient centrifugation, incubated with small 
unilamellar liposomes in vitro for 1 hour, labeled with 51Cr and injected 
into a cohort group of rats. One hour post-injection the spleen, liver, 
lungs, blood and bladder contents were removed and percentages of the 
recovered dose localized per total organ (%RD) were determined. The 
RES index, defined as %RDliver + %RDspleen, were 24.8 ± 4.5 and 20.5 ± 5.0 
for the control platelets and liposome-loaded platelets, respectively. These 
results indicate that liposome uptake does not enhance RES uptake. 
INTRODUCTION 
Liposomes have been used to deliver diagnostic and therapeutic drugs 
with moderate success. Reticuloendothelial system (RES) uptake and lack 
of targeting specificity of the liposomes have been the major problems 
encountered. Several groups have increased the circulation times by 
attaching either polyethylene glycol (PEG) or the ganglioside GM1 to the 
liposome surfaces (1,2); the circulation half-lives for distearoyl-
phosphatidylcholine (DSPC): cholesterol:PEG and GM1 liposomes are 20.0 
± 3.5 and 16.4 ± 3.1 hours, respectively, as compared to 6.7 ± 4.5 hours for 
DSPC:cholesterol (2:1 mole ratio) liposomes (1). There have been some 
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attempts to target specific tissue sites by the addition of ligands, such as 
human gamma globulin or aminomannose; however this increased 
targeting has been largely limited to increased Kupffer cell and 
reticuloendothelial system (RES) uptake (3,4) Addition of antibodies to 
the liposomes increases targeting specificity, but success has been limited 
since the liposomes are still prone to RES uptake (5). 
Recently we studied the in vitro interactions of small unilamellar 
vesicles (SUV) with platelets with the objective of developing an effective 
drug delivery system. Specifically, we have examined the kinetics and 
mechanisms of uptake of SUV, with and without covalently attached 
ligands. Liposomes that have been studied include: DSPC:cholesterol (2:1 
mole ratio) control liposomes (6) and aminomannose- , human gamma 
globulin- and transferrin-labeled control liposomes (7). From our data we 
have concluded that attachment of these surface ligands increases the 
targeting specificity and efficiency of in vitro platelet uptake. In addition 
the mechanisms of uptake and subsequent specific localization of the 
liposomes and their contents within the cells are dependent on the type of 
liposome used. 
Platelets have the unique ability to target specific sites in vivo 
including areas of infection and inflammation, tumors and clots. 
Therefore we expect to combine this in vivo targeting capability with the 
propensity of the platelets to take up liposomes in vitro in order to create 
an effective drug delivery system for diagnostic and therapeutic agents. 
Having a variety of trial liposome systems should be advantageous in the 
optimization of parameters for drug delivery. 
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In vitro functional assays, including microaggregation, serotonin 
release and membrane integrity, suggest that platelet function is not 
inhibited by liposome uptake (6, 7). The present study was designed to 
determine whether uptake of liposomes enhances rat platelet RES 
clearance. 
MATERIALS AND METHODS 
Control Liposome Preparation. A chloroform solution of a 2:1 mole ratio 
of DSPC (Avanti Polar-Lipids, Inc.) and cholesterol (cell culture tested 
Sigma Chemical Co.) was prepared such that the total lipid content was 
approximately 20 mg. The solution was taken to dryness in a 100 ml 
round bottom flask with a Buchler "Rotovap" apparatus and was dried in 
a dessicator under vacuum overnight. The resulting phospholipid 
mixture was resuspended in 5 ml of PBS (0.90% NaCl: 0.12% 
Na2HP04·7H20: 0.013% NaH2P04·H20 w /w in water, pH=7.3), vortexed 
and 2.5 ml portions sonicated for 15 minutes using a Heat Systems-
Ultrasonics, Inc. sonicator with a microprobe. In the studies examining 
liposome uptake versus incubation time and liposome concentration, five 
~Ci of [3H]cholesterylhexadecyl ether (New England Nuclear) were also 
added to the lipid prior to drying. 
Determination of Liposome Diameters and Estimation of Liposome 
Numbers. Liposome diameters for different preparations were 
determined by photon correlation spectroscopy at 480 run with a Malvern 
Instruments PCS 100 system. The numbers of [3H]cholesterylhexadecyl 
ether labeled liposomes were calculated by assuming that the counts per 
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weight lipid were constant for all preparations, the average surface area for 
a phospholipid molecule is 0.7 nm2 (8), and the average molecular weight 
for the lipid is 656 g/mol. The numbers of non-radiolabeled liposomes 
were determined by performing Bottcher phosphate assays (9) on the 
samples and assuming a 0.7 nm2 phospholipid surface area. The light 
scattering data indicated that liposome diameters were 68-80 nm. The 
numbers of liposomes reported have all been normalized assuming that 
the diameters of the liposomes for all experiments were 74 nm. 
Platelet Rich Plasma Isolation. Male Sprague-Dawley rats weighing 
approximately 250 g were anesthetized with ether. Blood was collected 
using a 10 ml syringe with an 18 gauge needle that contained 0.2 ml of a 
19% citrate solution from the posterior vena cava at kidney level. The 
needle was removed and the blood was dripped slowly into a centrifuge 
tube containing 2 ml of BSG-citrate solution (6.83 g NaCl, 4 g sodium 
citrate, 2.0 g dextrose, 0.218 g H2KP04 and 1.22 g HNa2P04 adjusted to 1 
liter H 20, pH 7.4). After slow inversion of the tube twice, an additional 2 
ml of BSG-citrate was added. Each blood sample was kept separate 
throughout the following centrifugation: 150 x g for 3 minutes to obtain 
the platelet rich plasma (PRP). The remaining red blood cell fraction was 
resuspended in 9 ml BSG-citrate and centrifuged again under the same 
conditions. The PRP samples from each rat were pooled. 
51 Chromium Labeling. 0.5 mCi of sodium 51 chromate was added to the 
PRP and incubated at room temperature for 30 minutes. 
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Platelet Isolation. STRactan gradients were prepared as follows . A stock 
solution of 30% STRactan (arabinogalactan, St. Regis, Tacoma, W A) was 
prepared in BSG-citrate and kept frozen until used. 10% and 20% 
solutions were prepared immediately before use by dilution with BSG-
citrate. Three ml of the 10% STRactan solution were added to 15 ml 
polypropylene centrifuge tubes. Four ml of the 20% STRactan solution 
were carefully layered on the bottom of the tubes. Three ml of the 51Cr 
labeled PRP were layered on top of the other layered solutions and the 
tubes were centrifuged at 700 x g for 20 minutes. The cloudy layers of 
platelets were removed, pooled, resuspended in 9 ml of BSG-citrate and 
centrifuged at 500 x g for 10 minutes to wash off the remaining STRactan. 
The cells were resuspended in modified Tyrodes solution (1.0 g dextrose, 
1.0 g NaHC03, 0.2 g KCl, 8.0 g NaCl, 0.05 g Na2HP04 and 0.14 g CaCl2 in 1lit 
H20, pH 7.4). 
Incubation with Liposomes. Platelets were incubated with liposomes at 
37oc for 1 hour. One hour allows significant uptake while minimizing 
platelet exposure to 37°C which has been shown to induce platelet 
membrane lesions (6) . Throughout the experiments we attempted to 
incubate a constant ratio of 2.1 x 1012 liposomes to 2.0 mg platelet protein 
(0.81 x 109 rat platelets/mg protein (10)). After incubation, 9 ml of BSG-
citrate was added to each tube prior to centrifugation at 500 x g for 10 
minutes to inhibit aggregation. Centrifugation was repeated and the cells 
were finally resuspended in BSG-citrate. The Peterson modification of the 
Lowry protein assay with a bovine serum albumin standard and without 
84 
trichloroacetic acid precipitation was used to estimate the amounts of 
protein in the samples (11). 
Organ Distribution. The rats were anesthetized with 30 mg nembutal/kg 
rat weight injected intraperitonially. Approximately 2 mg protein (0.5 ml) 
of control or liposome-loaded platelets were injected into each rat via the 
saphenous vein using a 1 ml syringe with a 23 gauge needle. Sufficient 
control and liposome-loaded platelets were retained to determine the total 
injected dose. Platelet localization in the spleen, liver, lung and blood 
were determined one hour post-injection. Small amounts of tissue were 
repeatedly washed in cold isotonic saline, weighed and gamma counted. 
Preliminary studies have shown that repeated washings in 200-300 ml of 
saline is as effective as the whole organ perfusion in removal of blood-
borne radioactivity (12). The total volume of blood per rat was determined 
by assuming an 8% blood volume (ml) per kg rat body weight. Organ 
uptake of platelets is expressed as the mean percent of the recovered dose 
localized per total organ (%RD) ± the standard deviation and was 
compared by the t test utilizing a 95% confidence level. Platelet organ 
localization was evaluated in groups of six rats. 
RESULTS 
In vitro uptake of liposomes btj rat platelets. 1.6 x 109 rat platelets (-0.5 mL) 
were incubated with 7.1 x 1011, 2.1 x 1012 and 3.5 x 1012 liposomes for 1 
hour at 37oc. Uptake increased with increasing numbers of incubated 
liposomes (Figure 1). 
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Organ distributions. The %RD for the spleen, liver, lungs and blood were 
1.10 ± 0.28, 23.73 ± 4.21, 1.87 ± 0.36, and 52.83 ± 6.98 for the control platelets 
and 0.93 ± 0.22, 19.62 ± 4.82, 1.55 ± 0.40, and 59.18 ± 7.96 for the liposome-
loaded platelets (Figure 2). The RES indexes, defined as the combined 
%RD of the liver and spleen, were 24.8 ± 4.5 and 20.5 ± 5.0 for the control 
platelets and liposome-loaded platelets, respectively. 
The data are reported as the percentage of the recovered dose rather 
than the injected dose to avoid possible misleading results due to the 
presence of unincorporated 51Cr. By combining the counts recovered from 
the bladder and kidneys plus those in the spleen, liver, lungs and blood 
(recovered dose), we account for greater than 75% of the injected dose. 
DISCUSSION 
The requirements for liposome-loaded platelets to be a successful drug 
delivery system are efficient loading without loss of platelet function and 
targeting capability. The in vitro function assays with human platelets, 
including microaggregation, serotonin release and membrane integrity 
suggest that platelet function is unimpaired by liposome uptake (6). 
The current study has demonstrated that liposome uptake does not 
enhance platelet RES uptake or decrease circulation. Initial uptake by the 
liver and spleen within the first 15 minutes is not uncommon. It is 
hypothesized that during this time platelets that are minimally damaged 
undergo repair and are rereleased (13). However, subsequent 
accumulation of platelets in the RES is often indicative of irreversible 
platelet damage (14, 15). Localization within the lungs can indicate platelet 
aggregation and formation of microemboli (12). No significant differences 
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in the organ distributions or the RES indexes have been demonstrated in 
our studies. Therefore, we conclude that liposome uptake does not impair 
platelet function or circulation. 
The ability to target might be dependent on factors other than those 
responsible for normal circulation. Therefore future studies will focus on 
experiments that assess the ability of the liposome-loaded platelets to 
target thrombi and tumors. Additionally, imaging thrombi and tumors 
using liposome-encapsulated imaging agents, including contrast dyes or 
radiolabels, will be examined and compared to conventional techniques. 
The efficacy of delivery of thrombolytic and anti-cancer drug using this 
method will be addressed in detail. 
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Figure 1. Liposome concentration dependence of Spraque-Dawley rat 
platelet uptake of [3H]cholesterylhexadecyl ether labeled liposomes. 1.6 x 
10 9 platelets were incubated with varying amounts of 
























Figure 2. Organ distributions of control and liposome-labeled platelet one 
hour post-injection. The data are represented as the percentage of the 
recovered dose localized per total organ (%RD) ± SD. 
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CHAPTER FIVE 
UPTAKE OF LIPOSOMES WITH COVALENTLY ATTACHED 
LIGANDS BY HUMAN PLATELETS 
R. Male, W. E. Vannier, T. Derrington and J.D. Baldeschwieler 
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ABSTRACT 
We have shown that the addition of human gamma globulin (HGG), 
transferrin (Tf) and aminomannose (Am) to the liposome surface 
enhances platelet uptake. Incubation of human platelets with HGG and Tf 
liposomes resulted in the uptake of the liposomes and retention of the 
lipid and release of the aqueous-phase components. The lipid label 3H-
cholesterylhexadecyl ether and water-soluble 3H-inulin were used to study 
the fate of the liposome components. Uptake of the HGG and Tf 
liposomes was proportional to the incubation time and liposome 
concentration. Approximately 1400 HGG and 550 Tf liposomes were taken 
up within a 5 hr incubation period. Uptake of the Am liposomes 
increased initially, but then decreased with time. Uptake was proportional 
to the number of liposomes added. Approximately 1000 liposomes were 
associated with each platelet after a 5 hour incubation period. 
INTRODUCTION 
Previous studies have demonstrated the platelets' ability to 
phagocytose small unilamellar distearoylphosphatidylcholine (OSPC): 
cholesterol (2:1 mole ratio) vesicles (1). Uptake of the liposomes occurred 
through the open channel system (OCS), and was followed by 
accumulation and degradation within acid-containing vacuoles. The lipid 
was retained; the aqueous components were exocytosed with a half-life of 
4 hours. Approximately 250 liposomes per platelet were taken up within 
a 5 hour incubation period. Uptake of the liposomes did not inhibit 
platelet function, as assessed by the serotonin release, microaggregation 
and fluorescein diacetate assays. 
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Although several therapeutic and diagnostic drugs would be well 
suited to this liposome-loaded platelet delivery system, delivery of other 
drugs via this method might not be ideal. Exposure to low pH may 
inactivate the drugs and the release times from the platelets following 
uptake may be too fast or slow. Therefore we developed new liposomes 
which are taken up more avidly than the DSPC:cholesterolliposomes and 
have different uptake and exocytosis mechanisms and possibly different 
intracellular fates . Specifically, we have studied the uptake of human 
gamma globulin (HGG), transferrin (Tf) and aminomannose (Am) 
liposomes (Figure 1). These ligands were chosen because previous studies 
with macrophages have demonstrated enhanced uptake, as compared to 
DSPC:cholesterol liposomes (2-4), and their ability to undergo receptor-
mediated endocytosis, which might offer alternative uptake and exocytosis 
pathways as compared to platelet phagocytosis of the ligand-free 
liposomes. HGG, the principle antibody in the serum, binds to foreign 
materials and results in their recognition by Fe receptors on phagocytic 
cells and complement proteins. Tf receptors bind transferrin-bound iron 
and endocytose the complex; the iron is internalized and the receptor is 
recycled within minutes. The receptor(s) for Am has not been 
determined. 
MATERIALS AND METHODS 
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Purification of Platelets. Platelets purchased from the American Blood 
Institute (Los Angeles) were centrifuged at 1000 g for 15 minutes in an IEC 
Centra-8 centrifuge. The pellet was resuspended in either 0.9% saline solution or 
Tyrodes buffer and spun at 110 g for 5 minutes to remove excess red blood cells . 
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The supernatant was spun at 450 g for 10 minutes. The pellet was resuspended 
in modified Tyrodes buffer (Tyrodes buffer plus 1.26 mM of CaC12). 
The final purities of the platelet preparations were greater than 95% platelets as 
assessed by a Colter S+4 Cell Counter; the main contaminants were red blood 
cells. Platelets were used within 24 hours of blood collection; this time was 
required for HIV and hepatitis testing. 
Determination of the Number of Platelets per mg of Protein. Cell counts were 
performed with a Coulter S+4 Cell Counter to determine the number of platelets. 
The Peterson modification of the Lowry protein assay (5) with a bovine serum 
albumin standard and without TCA precipitation was used to determine the 
amounts of protein in the same samples. A milligram of protein was found to 
correspond to 3 x 108 platelets. In addition the Lowry protein assay was used to 
determined the number of HGG and Tf ligands per liposome. 
Preparation of the Liposomes. MBPE liposomes. A mixture of 16 mg 
distearoylphosphatidylcholine (Avanti Polar-Lipids, Inc.), 3.9 mg cholesterol (cell 
culture tested Sigma Chemical Co.) and 0.94 mg maleamidobutyryl phosphatidyl 
ethanolamine (MBPE) (Avanti Polar-Lipids, Inc.) in chloroform was made. The 
solution was then taken to dryness in a 100 ml round bottom flask with a 
Buchler "Rotovap" apparatus and was dried in a dessicator under vacuum 
overnight. The resulting phospholipid mixture was resuspended in isotonic 
saline or 5 ml of PBS (0.90% NaCl: 0.12% Na2HP04·7H20: 0.013% NaH2P04·H20 
w /w in water, pH 7.3), heated to 60°C, vortexed and 2.5 ml portions probe 
sonicated for 15 minutes using a Heat Systems-Ultrasonics, Inc. sonicator with a 
microprobe. 
HGG and Tf coupling. Fifteen mg of heated aggregated HGG, prepared by 
heating a 30-50% HGG solution at 62°C for 30 minutes, or Tf was thiolated with 4 
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~L of N-succinimidyl-5-acetylthioacetate (SATA), 2.7 mg/50 ~L DMF. The 
resultant thiolated compounds were separated from free SATA by gel filtration 
on a Sephadex G-25 column. The liposome coupling reaction was performed by 
addition of 5 mg of the SATA-HGG or SATA-Tf to 5 ml of the sonicated MBPE-
liposomes and 0.2 ml of 0.5 M hydroxylamine, pH 7.2. The mixture was 
incubated with gentle mixing at room temperature for 1 hour. The reaction was 
terminated by the addition of 0.2 ml of 1 mg/ml N-ethylmaleimide. Free HGG 
or Tf was separated from the liposomes by gel filtration on a BioGel A 5m 
column (Figure 2). The number of ligands per liposome were approximately 140 
and 210 or 420 11g HGG/~-tmole P04 and 260 11g Tf/).lmole P04 for the HGG and Tf 
liposomes, respectively, assuming a molecular weight of 150,000 for the heat 
aggregated HGG and 90,000 for Tf. 
Aminomannose Liposomes. 3.36 mg of an aminomannose cholesterol 
derivative was added to 16 mg DSPC and 1.96 mg cholesterol. Liposomes were 
prepared as for the MBPE liposomes. The number of Am ligands per liposome 
surface was approximately 5,000. 
3 H-cholesterylhexadecyl ether Labeled Liposomes. Five microcuries of 3H-
cholesterylhexadecyl ether (New England Nuclear) in chloroform was added to 
the lipid mixture prior to drying and desiccation. Liposomes containing 3H-
cholesterylhexadecyl ether were resuspended in PBS. 
3H-inulin Labeled Liposomes. Two humdred fifty microcuries of 3H-inulin 
(Amersham, Corp.) was added to the resuspension buffer after desiccation. 
Liposomes containing 3H-inulin were resuspended in isotonic saline. Excess 3H-
inulin, (molecular weight 5,200) was separated from the liposomes by gel 
filtration with a Sephadex G-50-100 column. The percent encapsulation was 
approximately 15%. 
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Non-radiolabeled Liposomes. The liposomes were prepared as described but 
without the tritiated labels. 
Incubation Procedure. The platelets and liposomes were incubated at 37oc in 
1.5 mL polypropylene centrifuge tubes for the desired incubation times after 
which the mixtures were centrifuged at 5700 g for 5 minutes in a Beckman 
Microfuge 11. The pellets were washed twice in buffer and finally resuspended 
in 0.5 M NaOH/0.5% SDS and incubated overnight at room temperature. The 
solution was transferred to liquid scintillation vials with 10 mL of Safety Solve 
(Research Products, Inc.), mixed and allowed to sit at least two hours prior to 
scintillation counting. For each experiment all samples were done in duplicate; 
the number of independent experiments, n, are noted in the figure captions or in 
the text. Bars on the graphs represent the range of the data. 
Exocytosis Studies. Platelets and liposomes were incubated as above for 3 
hours. The mixtures were centrifuged and the platelets washed by centrifugation 
twice in buffer to remove excess liposomes and further incubated at 370C for 
varying periods of time. Both the pellets and supernatants were collected by 
centrifugation, solubilized in the NaOH/SDS solution overnight and counted. 
Determination of Liposome Diameters and Estimation of Liposome Numbers. 
The liposome diameters for different preparations were determined by photon 
correlation spectroscopy at 480 run using a Malvern Instruments PCS 100 system. 
The numbers of 3H-cholesterylhexadecyl ether labeled liposomes were calculated 
by assuming that the counts per weight of lipid were constant for all 
preparations, the average surface area for a phospholipid molecule is 0.7 nm2 (6) 
and the average molecular weight for the lipid is 656 g/mole. The numbers of 
3H-inulin labeled and non-radiolabeled liposomes were determined by 
performing Bottcher phosphate assays (7) on the samples and assuming a 0.7 
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nm2 phospholipid surface area. The light scattering data indicated that the HGG, 
Tf and Am liposomes diameters were 200-300 nm, 110-130 nm and 90-110 nm, 
respectively. The number of liposomes reported have all been normalized 
assuming that the diameters of the liposomes for all experiments were 74 nm, so 
that the data could be compared with previous data involving 74 nm 
DSPC:cholesterol (2:1 mole ratio) liposomes (1). 
In vitro Studies to Assess Platelet Function. Serotonin Release Assay. The 
serotonin assay was performed with 3 x 108 platelets, suspended in modified 
Tyrodes and incubated with or without 1.4 x 1012 liposomes, for one to nine 
hours as described (8). 0.5 J.!M 14C-serotonin was preincubated with the platelets 
for 20 minutes at 37°C; 1 J.!M imipramine was then added to prevent reuptake of 
secreted serotonin. Subsequent release from the alpha granules, an indication of 
degranulation, was measured. 
Microaggregation Assay. Platelets suspended in modified Tyrodes solution 
were incubated at 37oc, with or without 1.4 x 1012 liposomes, for one to nine 
hours and then fixed with 1% glutaraldehyde. The percentages of 
microaggregated platelets were determined by examining the cells in a 
hem a cytometer. 
RESULTS 
HGG Liposomes. 3 H-cholesterylhexadecyl ether Labeled Liposome Uptake. 
Platelet uptake of 3H-cholesterylhexadecyl ether labeled liposomes increased with 
increasing incubation times (Figure 3). After incubation with 3 x 108 platelets for 
5 hours, approximately 1400 3H-cholesterylhexadecyl ether labeled liposomes 
were associated with each platelet. 3H-cholesterylhexadecyl ether labeled HGG 
liposome uptake by platelets also increased with increasing numbers of incubated 
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liposomes; two incubation times are shown (Figure 4). Incubation for 12 hours 
resulted in greater uptake than the 2.0 hour incubation. 
3H-inulin Labeled Liposome Uptake. Although the number of 3H-inulin 
labeled liposomes taken up increased with time (Figure 3), the kinetics of uptake 
were different from that for the 3H-cholesterylhexadecyl ether labeled liposomes. 
Incubation of 3 x 108 platelets with 7.1 x 1011 liposomes resulted in the uptake of 
approximately 500 liposomes per platelet after 5 hours. The uptake of 3H-inulin 
labeled liposomes versus the concentration of liposomes incubated is shown for 
two different incubation times (Figure 5). Uptake was proportional to both the 
number of liposomes and incubation time. The difference in kinetics of uptake 
as assessed by the lipid label and the aqueous label suggests that there is a 
difference in the fate of the lipid and aqueous components after platelet uptake. 
Release of Tritiated Radiolabels To study the possible exocytosis of 
liposomes, the amounts released of the tritiated radiolabels 3H-
cholesterylhexadecyl ether and 3H-inulin were examined (Figure 6). After 7 
hours no membrane associated probe was released. However, up to 34% of the 
aqueous-phase probe was released during this period. 
Free HGG and mAb IV.3 Inhibition. HGG is known to interact with Fe 
receptors on cells. Therefore, to determine if uptake of the HGG liposomes was 
via a Fe receptor, free HGG or mAb IV.3 (Medarex, Inc. NH), an antibody to 
platelet Fe receptor, were incubated with the platelets for 20 minutes prior to 
incubation with the liposomes. Incubation with 40 or 100 r..tg HGG decreased 
uptake by an average of 14.0 ± 7.5% and 21 ± 7.3% respectively (n=2). Addition 
of 5 1-1g of mAb IV.3 decreased uptake by 13.7 ± 6.7% (n=2). Platelets are known to 
contain at least two different Fe receptors (9,10); therefore it is not surprising that 
addition of an antibody, which is specific to only one of the receptors, decreased 
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uptake by only 13%. Previous studies demonstrated that binding of fluorescently 
labeled HGG to platelets was inhibited 25% by the addition of a hundred-fold 
excess of free HGG or a 3-fold excess of mAb IV.3 (11). 
Tf Liposomes. 3H-cholesterylhexadecyl ether Labeled Liposome Uptake. Platelet 
uptake of 3H-cholesterylhexadecyl ether labeled liposomes increased with 
increasing incubation times (Figure 7) and increasing number of incubated 
liposomes (Figure 8). After incubation of 7 .1 x 1011 liposomes with 3 x 108 
platelets for 5 hours, approximately 550 3H-cholesterylhexadecyl ether labeled 
liposomes were associated with each platelet. Incubation for 12 hours resulted 
in greater uptake than the 2.0 hour incubation. 
3H-inulin Labeled Liposome Uptake. Uptake of 3H-inulin labeled liposomes 
increased with time (Figure 7), but was less than that for the 3H-
cholesterylhexadecyl ether labeled liposomes. Incubation of 3 x 108 platelets with 
7.1 x 1011 liposomes resulted in the uptake of approximately 350 liposomes per 
platelet after 5 hours. The uptake of 3H-inulin labeled liposomes versus the 
concentration of liposomes incubated is shown for two different incubation 
times (Figure 9). Uptake was proportional to both the number of liposomes and 
incubation time. Similar to the HGG liposomes, the difference in uptake of the 
lipid and the aqueous labels suggests that the fate of the Tf liposome lipid and 
aqueous components after platelet uptake are different. 
Release of Tritiated Radiolabels To study the possibe exocytosis of liposomes, 
the amounts released of the tritiated radiolabels 3H-cholesterylhexadecyl ether 
and 3H-inulin were examined (Figure 10). After 7 hours no membrane 
associated probe was released. However, up to 32% of the aqueous-phase probe 
was released during this period. 
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Free Tf Inhibition. Some cells contain Tf receptors; as of now, the presence of 
Tf receptors on platelets has not been demonstrated. The addition of 25, 50 or 
100 J-Lg free Tf, which is sufficient to block 106 receptors per platelet, does not 
inhibit uptake (n=2). It is possible that the Tf liposomes are going through the 
OCS and phagocytic pathway like the non-ligand DSPC:cholesterol (2:1 mole 
ratio) liposomes (1) and/or a Tf-independent receptor. 
Aminomannose Liposomes. 3H-cholesterylhexadecyl ether Labeled Liposome 
Uptake. Platelet uptake of 3H-cholesterylhexadecyl ether labeled Am liposomes 
decreased with increasing incubation times after an initial uptake period; three 
incubation concentrations are shown (Figure 11). Overall, uptake increased with 
increasing numbers of incubated liposomes (Figure 12). Incubation of 7.1 x 1011 
liposomes with 3 x 108 platelets for 1 hour resulted in the uptake of 
approximately 1400 liposomes per platelet. After 5 hours, 1000 liposomes are 
associated with each platelet. 
3H-inulin Labeled Liposome Uptake. Uptake of 3H-inulin labeled liposomes 
also decreased with time (Figure 13), and was approximately the same as for the 
3H-cholesterylhexadecyl ether labeled liposomes. The uptake of 3H-inulin 
labeled liposomes versus the concentration of liposomes incubated is shown for 
two different incubation times (Figure 14). 
In vitro Assays to Assess Platelet Function. Incubation with 14 x 1011 HGG, 
Tf or Am liposomes with 3 x 108 platelets for 0 to 9 hours did not significantly 




In our original study we examined the uptake of DSPC:cholesterol (2:1 mole 
ratio) small unilamellar liposomes by human platelets (1). We were able to 
demonstrate that the liposomes entered the open channel system, accumulated 
in acid-containing vacuoles and were degraded. The lipid was retained; the 
aqueous components were exocytosed. The purpose of this study was to 
incorporate ligands on the surface of the liposomes with the hope of enhancing 
platelet uptake and modifying the intracellular fates of the liposomes. It is likely, 
in addition to other mechanisms, that a fraction of the ligand-liposomes are 
internalized by phagocytosis. 
Uptake at 5 hours for 74 nm non-ligand liposomes is approximately 250 
liposomes per platelet as compared to 1400, 550 and 1000 for the HGG, Tf and Am 
liposomes, respectively. These numbers were normalized, assuming that the 
diameters of the liposomes for all experiments were 74 nm, to allow comparison 
of the data between the two studies. The size of the ligand liposomes actually 
range between 200-300 nm for the HGG liposomes, 110-130 nm for the Tf 
liposomes and 100-120 nm for the Am liposomes. Therefore, we prepared 120 
nm and 250 nm non-ligand liposomes and studied their uptake by platelets. The 
uptake of 120 nm and 250 nm non-ligand liposomes are 2 and 4 times greater 
than the uptake of 74 nm non-ligand liposomes. Therefore more accurate 
comparisons are 1400 and 1000 HGG and non-ligand liposomes per platelet, 
respectively, and 550, 1000 and 500 Tf, Am and non-ligand liposomes per platelet, 
respectively. The above uptake values, as well as all others in this paper, 
represent both incorporated and bound liposomes. 
Without further experiments, the mechanisms of HGG, Tf and Am liposome 
uptake can only be hypothesized. The fact that the aqueous probe is selectively 
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released while the lipid is retained, strongly suggests that the HGG and Tf 
liposomes are internalized and degraded. Our data also strongly suggest that the 
HGG liposomes bind and are possibly endocytosed via a Fe receptor pathway 
since the addition of free HGG or mAb IV.3, an antibody directed against the Fe 
receptor, inhibits uptake. The uptake of Tf liposomes is not inhibited by the 
addition of free Tf and may be internalized via platelet phagocytosis or another 
Tf-independent pathway. 
The mechanism of the aminomannose liposome interaction with platelets is 
not readily apparent. Since the uptake, as measured by the lipid and aqueous 
probes are identical, it would appear that the fates of the lipid and aqueous probes 
are identical. If the liposomes bind and then unbind, the concentration of the 
bound liposomes versus time should increase and then reach a steady state. 
However, the number of platelet associated liposomes does not plateau. If the 
liposomes are internalized intact and are released in such a state that they can 
not rebind or the receptor is altered to prevent rebinding, then the uptake could 
be described as a consecutive first order reaction kinetic scheme with 
. k 1 [liposomes]o . 
[hposome]bounct = (exp(-k1t)- (exp(-k2t)). The uptake prof1les for 17.8 
(k2- k l) 
x 1011 and 35.5 x 1011 incubated liposomes are identical in shape and vary in 
amplitude as expected from the above equation, but the uptake for 7.1 x 1011 
liposomes is very different in shape as well as amplitude. Another possible 
explanation for the data is that the liposomes are interacting with more than one 
type of receptor. Possible receptors include a mannose receptor (12), known to 
exist on macrophages and other cells, or a positive charge dependent receptor. 
Perhaps at lower concentrations the liposomes bind to the receptor with the 
highest binding constant; at higher concentrations other receptors w ith lower 
binding constants become involved. Although it seems unlikely that a factor of 
106 
2.5 change in the initial liposome concentration could result in the binding to an 
additional receptor, the uptake versus concentration data also support the idea 
that the mode of uptake changes between the concentrations of approximately 14 
x 1011 and 19 x lOllliposomes. Below 14 x lOllliposomes the uptake at 2 hours 
exceeds that at 12 hours; above 19 x 1011 liposomes the uptake at 12 hours is 
greater than that at 2 hours. 
The ability to encapsulate a variety of therapeutic and diagnostic in vitro and 
to target specific locations in vivo such as areas of inflammation or infection, 
neoplastic tumor cells, or thrombosis would be of great medical importance. The 
efficacy of using liposome-loaded platelets will be highly dependent on the 
concentration of drug per platelet, which is related to the number of liposomes 
per platelet, and the intracellular location of the drug, which is related to the 
mechanism of uptake. In addition, it may be possible to achieve sufficient 
platelet targeting specificity by manipulation of the liposome surface ligands so 
that the liposomes can be injected directly and load platelets in vivo. 
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Figure 1: Structures of the human gamma globulin (HGG) and 
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Figure 2: Synthesis scheme for the attachment of HGG and Tf to the 




























Figure 3: Platelet uptake of 3H-cholesterylhexadecyl ether <•) (n=6) and 3H-
inulin (0) (n=3) HGG liposomes versus time. 3 x 108 platelets were incubated 











































































Figure 4: Platelet uptake of 3H-cholesterylhexadecyl ether HGG liposomes 
versus liposome concentration. 3 x 108 platelets were incubated with varying 










































































Figure 5: Platelet uptake of 3H-inulin HGG liposomes versus liposome 
concentration. 3 x 108 platelets were incubated with varying numbers of 
liposomes at 37°C for 2 (•) and 12 hours (0) (n=4). 
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Figure 6: Release studies of lipid and aqueous probes. 3 x 108 platelets were 
incubated with 14 x 1011 3H-cholesterylhexadecyl ether (•) or 3H-inulin (0) HGG 
liposomes at 37°C for 3 hours. Cells were pelleted, washed twice with buffer, 
resuspended in buffer, and incubated for various incubation times at 37°C. 
Percentages of 3H-cholesterylhexadecyl ether and 3H-inulin in the supernatants 
were determined (n=4). 




































Figure 7: Platelet uptake of 3H-cholesterylhexadecyl ether (•) (n=4) and 3H-
inulin (0) (n=3) Tf liposomes versus time. 3 x 108 platelets were incubated with 











































































Figure 8: Platelet uptake of 3H-cholesterylhexadecyl ether Tf liposomes 
versus liposome concentration. 3 x 108 platelets were incubated with varying 











































































Figure 9: Platelet uptake of 3H-inulin Tf liposomes versus liposome 
concentration. 3 x 108 platelets were incubated with varying numbers of 
liposomes at 37°C for 2 (•) and 12 (0) hours (n=2). 
























Figure 10: Release studies of lipid and aqueous probes. 3 x 108 platelets were 
incubated with 14 x 1011 3H-cholesterylhexadecyl ether C•) or 3H-inulin (0) Tf 
liposomes at 37°C for 3 hours . Cells were pelleted, washed twice with buffer, 
resuspended in buffer, and incubated for various incubation times at 37°C. 
Percentages of 3H-cholesterylhexadecyl ether and 3H-inulin in the supernatants 






















































Figure 11: Platelet uptake of 3H-cholesterylhexadecyl ether Am liposomes 
versus time. 3 x 108 platelets were incubated with 7.1 x lOll (•) (n=6), 17.8 x 1011 










































































Figure 12: Platelet uptake of 3H-cholesterylhexadecyl ether Am liposomes 
versus liposome concentration. 3 x 108 platelets were incubated with varying 
numbers of liposomes at 37°C for 2 (•) and 12 (0) hours (n=4). 





































Figure 13: Platelet uptake of 3H-inulin Am liposomes versus time. 3 x 108 



































































































Figure 14: Platelet uptake of 3H-inulin Am liposomes versus liposome 
concentration. 3 x 108 platelets were incubated with varying numbers of 
liposomes at 37°C for 2 (•) and 12 hours (0) (n=4). 
CHAPTER SIX 
CHARACTERIZATION OF THE INTERACTION OF 
PLATELETS WITH SENDAI VIRUS 
Roxanne Male, Wilton E. Vannier, Qizhi He and John D. Baldeschwieler 
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ABSTRACT 
Sendai virus particles have been shown to infect cells via fusion of the 
viral envelopes with the cell plasma membranes. In addition it has been 
demonstrated that platelets are capable of phagocytosing particles 
including latex beads and small neutral unilamellar vesicles. Both 
possible mechanisms of Sendai virus interaction with human platelets 
were considered and fusion was found to be the predominant process. 
Incubation of platelets with 125I labeled Sendai virus particles (SV) and 
125I labeled reconstituted Sendai virus envelopes (RSVE) resulted in 
uptake of both the virus particles and RSVE. Uptake of the 125I labeled 
virus particles was proportional to the incubation time and amount of 
virus added. Incubation of 3 x 108 platelets with either 9.9 x 1010 125I 
labeled intact or reconstituted virus particles at 37° C for twelve hours 
resulted in approximately 125 RSVE per platelet and 50 virus particles per 
platelet. Uptake measurements of 125I labeled SV or RSVE do not 
distinguish between fusion and binding mechanisms. 
The octadecylrhodamine B (R1 3) fluorescence assay was used to 
demonstrate and characterize the fusion of virus particles with platelets. 
Fusion was found to be maximal at 37°C and pH 7.4. The maximum 
number of Sendai virus fusion sites per platelet was determined to be 
approximately 55 virus particles per platelet. 
INTRODUCTION 
Although the interaction of viruses, including Newcastle Disease 
Virus and Sendai virus (paramyxovirus), Influenza virus (myxovirus) 
and Human Immunodeficiency Virus Type 1 (retrovirus), with platelets 
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have been studied previously, little is known about the mechanisms of 
the interactions [1-4]. Thrombocytopenia is a prominent feature of many 
virus infections and it has been proposed that platelets may play an 
important role in the scavenging of virus particles from the circulation [5]. 
Removal of sialic acid residues from rabbit platelets, as a result of 
incubation with Newcastle Disease Virus (NDV), has been shown to result 
in rapid removal of these cells from circulation [6]. In addition, 
incubation of human platelets with Sendai virus (SV) in vitro has been 
shown to result in platelet aggregation and secretion, which usually 
promotes reticuloendothelial uptake. 
Influenza virus particles were observed by electron microscopy within 
the platelet open channel system (OCS) by Danon et al. as early as 1959 [7], 
but the mechanism of interaction between Influenza virus particles and 
platelets is still uncertain. Jerushalmy et al. hypothesized that Influenza 
virus and Newcastle Disease virus particles are incorporated inside 
platelets since neuraminidase treatment after virus incubation with the 
cells did not result in complete elution of either virus from the cells [2]. 
Using the neuraminidase elution technique, Terada et al. concluded that 
Influenza virus particles were absorbed to the platelet surface and do not 
undergo endocytosis [3]. 
Human Immunodeficiency Virus Type 1 (HIV-1) particles have also 
been observed within platelet vacuoles by electron microscopy [4] . 
We chose Sendai virus, a murine paramyxovirus, as a model virus to 
determine the mechanism and kinetics of virus interactions with 
platelets. Interactions of this virus with a variety of cell lines have been 
studied extensively by ourselves as well as others and are well 
138 
characterized [8-10]. Sendai virus particles are capable of fusing with cell 
membranes via the function of two glycoproteins [11-13]. The 
hemagglutinin I neuraminadase (HN) protein mediates binding of the 
virus particles to the cell surface receptors and the fusion (F) protein is 
essential for promotion of virus-cell fusion. 
In addition to viral fusion, we tested for possible phagocytosis of the 
Sendai virus particles by the platelets. Platelets are known to phagocytose 
a variety of particles, including liposomes and latex particles [14,15]. 
Although both processes can result in viral uptake, the characteristics of 
viral fusion and platelet phagocytosis are very different. Phagocytosis is 
energy dependent and is arrested when both oxidative phosphorylation 
and glycolysis are inhibited [16]. Phagocytosis is also calcium dependent 
[17] . Fusion is temperature and pH dependent [18] and requires the 
presence of functional F and HN proteins. 
MATERIALS AND METHODS 
Purification of Platelets. Platelets were purchased from the American 
Blood Institute (Los Angeles) and used within 10 hours of collection. This 
time was necessary for HIV and Hepatitis testing. The platelets, which 
were stored in citrate phosphate dextrose, were centrifuged at 1,000 g for 15 
minutes in a IEC Centra-8 centrifuge. The pellet was resuspended in 
Tyrodes buffer (0.1% dextrose, 0.1% NaHC03, 0.02% KCl, 0.8% NaCl and 
0.005% Na2HP04 w /w in 1 liter water, pH=7.4) and spun at 110 g for five 
minutes to remove all red blood cells . The supernatant was then 
centrifuged at 450 g for 10 minutes; the platelet pellet was resuspended in 
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Hank's Balanced Salt Solution (HBSS) or modified Tyrodes buffer 
(Tyrodes buffer plus 1.26 mM CaCl2). 
The final purity of the platelet preparation was greater than 95% 
platelets as assessed by a Coulter S+4 cell counter; the main contaminants 
were red blood cells. 
Determination of the N urn ber of Platelets per mg of Protein. Cell 
counts were performed with the Coulter S+4 Cell Counter to determine 
the number of platelets. The Peterson modification of the Lowry protein 
assay [19] with a bovine serum albumin standard and without TCA 
precipitation was used to determine the amounts of protein in the same 
samples. A milligram of protein was found to correspond to 3 x 108 
platelets. Meyers et al. reported a value of 5.8 x 108 platelets/mg protein 
[20]. However, they isolated the platelet in an excess of human serum 
albumin, which might not have been completely removed prior to the 
protein assay, and did not report the protein standard used. The ·assay is 
highly dependent on the molecular weight and aromatic amino acid 
content of the protein standard. 
Preparation of Sendai Virus. Ten day old chicken eggs were each 
injected with 200 microliters of a 1/500 dilution of Z strain Sendai virus 
(~1.3 x 1012 virus particles/ml) in PBS (0.90% NaCl, 0.12% Na2HP04·7H20, 
0.013% NaH2P04·H20 w /win water, pH 7.3) containing 1% penicillin and 
1% streptomycin. Prior to injection the solution was filtered through an 
800 nm millipore filter. The inoculated eggs were incubated at 370C for 
three days. The eggs were then frozen at -20°C for two hours to reduce 
bleeding during harvesting. The virus particles were harvested according 
to the protocols of Hoekstra et al. [18] and Maeda et al. [21]. The amounts 
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of protein in the preparations were determined using the Peterson 
modification of the Lowry protein assay. The virus fusion activities, as 
assessed by the Rts fusion assay, for the various preparations used varied. 
All data displayed in the same figures were taken from experiments which 
used the same virus preparations. 
1251 labeling of the Virus. Approximately 4 x 1012 SV or RSVE particles 
were mixed with 0.5 mCi of Na125J (Amersham, Corp.) in 0.5 mL of HBSS. 
Forty microliters of a 10 mg/ml solution of chloramine T were added and 
mixed gently for one minute. Subsequently two hundred microliters of a 
4 mg/ml solution of sodium metabisulfite were added and mixed gently 
for five minutes. Both solutions were made immediately before use. The 
virus particles were washed twice by centrifugation at 84,000 gin a L 5-65 
Beckman Ultracentrifuge using a SW 50.1 rotor for forty minutes to 
remove excess 125J and resuspended in HBSS. Labeling by this method 
did not appear to interfere with the virus particles' activities, as assessed by 
the Rts fusion assay. The specific proteins labeled and the activity per mg 
protein have been previously determined by Markwell et al. [22]. 
Preparation of RSVE. Reconstituted virus particles were prepared 
using a modification of the procedure of Vainstein et al. [23]. 3.9 x 1012 SV 
(2.6 x 1012 particles/ml solution) were pelleted at 84,000 g for 40 minutes at 
4oc. The pellet was resuspended in 100 microliters of a solution A (100 
mM NaCl, 10% Triton X-100, 0.1 mM phenylmethylsulfonyl fluoride 
(Sigma Chemical Co.) and 50 mM Tris HCl buffered to pH 7.4) and gently 
shaken for one hour at room temperature. The mixture was centrifuged 
under the same conditions as above; the supernatant was removed and 
shaken with 50 mg of SM-2 beads (Bio-Rad, Inc.) for 3-4 hours to remove 
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excess detergent. An additional 50 mg of beads and 100 microliters of 
solution B (100 mM NaCl, 50 mM Tris HCl and 5 mM EDTA buffered to 
pH 7.4) were then added and gently shaken for 12-14 hours. The 
supernatant was removed from the beads using a syringe and centrifuged 
at 84,000 g for 40 minutes at 4°C to obtain the reconstituted virus 
envelopes which were resuspended in solution B. 
Preparation of 3 H-inulin Labeled RSVE. 3H-inulin labeled 
reconstituted virus particles were prepared as above except 50 ~-tCi of 3H-
inulin (5,200 molecular weight) (Amersham, Corp.) was added to solution 
A. 
Incubation Procedure. The virus particles and platelets were incubated 
in 1.5 ml polypropylene centrifuge tubes for the desired incubation times 
and at the appropriate temperatures with occasional inversion, after 
which the mixtures were centrifuged at 5700 g for 5 minutes in a Beckman 
Microfuge 11. The pellets were washed twice in Tyrodes buffer and finally 
resuspended in 0.5 ml of 0.5 M NaOH/0.5% SDS and incubated overnight 
at room temperature. Solutions containing 1251 were gamma counted 
with a Beckman Biogamma II; · solutions containing 3H-inulin were mixed 
with 10 ml Safety Solve (Research Products, Inc.), allowed to sit for at least 
two hours and scintillation counted with a Beckman LS 6000. For each 
experiment, all samples were done in duplicate; the number of 
independent experiments (n) is noted in the figure legends or in the text. 
Bars on the graphs figures represent the range of the data. 
Exocytosis Studies. Platelets and 1251 labeled or 3H-inulin labeled 
reconstituted virus particles were incubated as q.bove for 12.0 hours. The 
mixtures were centrifuged and the platelets washed by centrifugation twice 
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in HBSS or modified Tyrodes buffer to remove excess RSVE and further 
incubated at 37°C for varying amounts of time. Both the pellets and 
supernatants were collected by centrifugation and solubilized in 
NaOH/SDS solution overnight. 
Octadecylrhodamine B (Rts> Fluorescent Assay. The fluorescent probe 
R1s has been used by a number of other workers to investigate viral fusion 
(for a general review see 8). The probe inserts spontaneously into the 
viral membrane and rapidly equilibrates throughout the target membrane 
when fusion occurs. The probe self-dequenches by resonance energy 
transfer and subsequent trivial decay mechanisms due to the overlap of 
the emission and excitation fluorescence bands. In dilute concentrations 
( <10% of the lipid content), the fluorescent dequenching is linearly 
proportional to the concentration of the probe in the membrane [24] . 
Upon fusion of the virus with a cell, the probe is diluted in the target 
membrane and is dequenched. 
A volume of ten microliters of a 1 mM solution of R1s (Molecular 
Bioprobes, Inc.) in ethanol was added to a one milliliter solution 
containing approximately 2.6 x 1012 SV (1 mg of protein= 1.3 x 1012 SV [25]) 
and incubated for one hour at room temperature. Excess R1s was removed 
by centrifugation at 84,000 g for 40 minutes at 4oc. The pellet was 
resuspended in HBSS or Tyrodes buffer. 
Fluorescence measurements were done with a SLM 4800 fluorimeter 
with a stirred, temperature controlled cuvette by monitoring the emission 
at 590 nm with an excitation wavelength of 560 nm. The temperature and 
pH dependences of fusion were determined by performing kinetic 
experiments of thirty minute duration. R1s labeled Sendai virus were 
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preincubated at the appropriate temperature in the cuvette with 2 ml of 
HBSS or Tyrodes buffer. Data collection was initiated and after a baseline 
had been established the platelets were added. At the conclusion of the 
experiments 1% Triton X-100 was added to determine the maximum 
fluorescence intensity. 
To determine the viral and platelet concentration dependences of 
fusion, R18 labeled Sendai virus particles were incubated with platelets at 
37oC for thirty minutes. Prior to and after incubation, fluorescence 
measurements were performed. One percent Triton X-100 was added to 
the samples at the conclusion of each experiment to determine the 
maximum fluorescence intensity. 
HPTS Labeled RSVE. HPTS, 1-hydropyrene-3,6,8-trisulfonic acid 
(Molecular Probes), is a pH-dependent fluorescent dye which exhibits two 
major fluorescence maxima (403 and 460 nm) which have a 
complementary pH dependence in the range 5-9; the peak at 403 is 
maximal at low pH while the peak at 460 nm is maximal at high pH 
values. The fluorescence values at 413 and 447 nm are relatively pH-
independent and can be used to standardize the concentration of dye 
associated with the cells. The fraction of dye taken up by phagocytosis and 
delivered to an acidic compartment is calculated using the 460/413 nm 
ratio (or 460 I 447 nm ratio) and the equation: 
Fraction phagocytosed = (ratiopH7.4-ratiomeasJ/ (ratiOpH7.4-ratiopH6.0) 
where ratiomeas. is the 460/413 ratio of the virus treated cells and ratiopH 
7.4 and ratiOpH 6.0 are the 460/413 ratios of virus in buffer and acidified 
buffer respectively. In the original paper by Daleke et al. [26], the second 
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peak occurred at 450 nm; however, according to our data the peak 
maximum is at 460 nm. 
HPTS labeled RSVE were prepared according to the procedure for 
RSVE using a modification of solution A (75 mM NaCl, 35 mM HPTS, 
10% Triton X-100, 0.1 mM PMSF and 50 mM Tris HCl buffered to pH 7.4). 
After incubation with HPTS labeled reconstituted virus env elopes for 
various times, the platelets were washed twice with buffer. Fluorescence 
excitation spectra (Aex 395-465 nm, 4 nm bandwidth) were measured at 510 
nm emission (4 nm bandwidth) using a SLM 4800 spectrofluorimeter 
(SLM Instruments, Inc.) with a stirred, temperature controlled cuvette 
(20°C). The 447 nm fluorescence values were used to standardize the data 
since degradation of the probe resulted in a peak at 432 nm which 
interfered with the readings at 413 nm used for data standardization. 
Control experiments were performed to assess the leakage of HPTS 
from the RSVE. No significant leakage occurred within 12 hours. 
Thin Section Electron Microscopy. Samples of 3 x 108 platelets were 
incubated with 1 x 1011 virus for 6 hours at 37oc and washed twice by 
centrifugation in Tyrodes buffer. The samples were incubated in 1% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 15 minutes and then 
centrifuged at 800 g . Postfixing in 2% osmium tetroxide was done in the 
dark at 4oC for 0.5 to 2 hours followed by centrifugation at 800 g and 
washing in the buffer. Dehydration was accomplished by immersing the 
sample in a series of solutions 50% through 100% in ethanol for 5 minutes 
each. At this point the sample was transferred to a gelatin capsule and 
centrifuged. LR white, the embedding agent, was added and crosslinked 
and dried at 4oC for 2-3 days under an ultraviolet lamp. Sliced sections 
145 
were stained with 2% uranyl acetate for 5 minutes, then rinsed 50 times 
and blotted dry. An 8 mM solution of acidic lead citrate was then added 
and rinsed thorough! y. 
In addition, platelets suspended in HBSS or modified Tyrodes buffer 
incubated with or without virus particles for 1 hour at 37oc and prepared 
as above were studied to determine changes in platelet morphology under 
the conditions used for studying the virus particle interaction. 
In vitro Studies to Assess Platelet Function. Serotonin Release Assay. 
The serotonin release assay was performed with 3 x 108 platelets (0.5 ml 
final volume), suspended in HBSS or modified Tyrodes buffer and 
incubated with or without 9.9 x 1010 Sendai virus particles for one to seven 
hours as described [27]. 14C-serotonin loaded platelets were prepared by 
preincubation in Tyrodes buffer containing 1 mM 14C-serotonin for 0.5 
hours, centrifugation to remove excess 14C-serotonin and resuspension in 
modified Tyrodes buffer containing 2 mM imipramine to prevent 
reuptake of the probe. 
Microaggregation Assay. Platelets suspended in HBSS or modified 
Tyrodes buffer were incubated at 37°C, with or without Sendai virus 
particles, for one to nine hours and then fixed with 1% glutaraldehyde. 
The percentages of aggregated platelets were estimated by examining the 
cells in a hemocytometer and using the equation, % aggregation = number 
of cells in aggregates/ total number of cells. 
RESULTS 
125J-labeled Virus Uptake Studies. To begin characterizing the uptake 
of Sendai virus by platelets, 125J-labeled virus particles were incubated 
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with platelets. The incubation time, concentration of the incubated virus 
and incubation temperature dependences were studied. The values 
reported for the uptake as determined by the use of 125! do not differentiate 
between binding, fusion and phagocytosis. 
Platelet uptake of the 125!-labeled virus particles increased with 
increasing incubation times over the 18 hour range studied. Uptake 
occurred rapidly during the first 3 hours, but then began to saturate (Figure 
1). After incubation of 3 x 108 platelets with 9.9 x 1010 virus particles for 12 
hours at 37°C, approximately 40 virus particles were associated with each 
platelet. Viral uptake increased with increasing numbers of incubated 
virus. Two incubation times are shown in Figure 2. Incubation for 17.5 
hours resulted in only slightly greater uptake values than the 12.5 hour 
incubation which suggests the onset of saturation during these incubation 
times. Uptake at 37oc, following incubation of 3 x 108 platelets with 
varying numbers of virus particles for 12 hours, was greater than uptake at 
4oc. At both temperatures the uptake increased with increasing numbers 
of incubated virus (Figure 3). The ratios of platelet associated virus 
particles to platelets were approximately 50 virus particles/platelet for 37oc 
and 25 virus particles/platelet at 4oc. 
Release Studies of the Lipid and Aqueous Compartments of the RSVE. 
To study the possible exocytosis of the reconstituted virus particles, the 
amounts of 125! and 3H-inulin released from platelets after 12.0 hours of 
incubation with reconstituted virus particles, two centrifugation washes 
and resuspension in buffer were examined (Figure 4). After 12 hours 
neither the membrane protein associated probe nor the aqueous phase 
probe was released. 
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Competition Assay. A competition assay was performed to study the 
saturation of viral uptake (data not shown, n=4). Preincubation of 3 x 108 
platelets with 0 to 2.0 x 1011 non-radiolabeled virus particles prior to 
incubation with 9.9 x 1010 125I-labeled virus particles for preincubation 
times of 0.5 and 6 hours and incubation times of 2 and 6 hours resulted in 
decreased uptake with increasing amounts of non-radiolabeled virus 
particles added. In addition, increased preincubation times resulted in less 
uptake of the labeled virus particles. 
Fusion of Virus With Platelets. The R18 fluorescence assay was 
employed to study fusion of Sendai virus particles with platelets and to 
characterize the temperature, pH and viral and platelet concentration 
dependences. Plots of the fluorescence versus time showed biphasic 
behavior for the fusion of virus particles with platelets. Initially the 
fluorescence increased rapidly for approximately two minutes and then 
continued at a slower rate of change until saturation. Fusion was 
maximal at 37°C and pH 7.4. The ranges of temperature and pH studied 
were 10°C to 50°C and 5 to 8 respectively (n=4). 
In addition, the percent fusion decreased with increasing numbers of 
virus particles added. The percent fusion is defined as: % Fusion = (F(t) -
F(I))/(F(T) - F(I)) where F(t) is the fluorescence at time t, F(I) is the initial 
fluorescence and F(T) is the total fluorescence. Incubation of 4.5 x 107 
platelets (1 mg of protein = 3 x 108 platelets [14]) with 6.5 x 109 to 3.9 x 1010 
virus particles (1 mg of protein = 1.3 x 1012 Sendai virus particles [25]) at 
37°C for 30 minutes resulted in a decrease in the percent fusion from 10% 
to 4% while the percent fusion remained constant at approximately 4% at 
4°C over the same range (Figure Sa). The percent fusion increased from 
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4% to 12% when 6.5 x 109 virus particles were incubated with 1.5 x 107 to 
6.0 x 107 platelets for 30 minutes at 37°C and decreased from 5% to 2% at 
4°C (Figure Sb). 
By replotting the data of figure 5 as a reciprocal plot we determined the 
maximum number of fusion sites per platelet from the values for the y-
intercept, the number of platelets per fused virus at infinite dilution. A 
reciprocal plot graphs the number of platelets per fused virus versus the 
number of platelets per virus added. Approximately 55 virus particles are 
capable of fusing with a platelet at 37°C. 
Inhibition of Viral Uptake. Fusion and platelet phagocytosis are two 
very different processes which can each be inhibited using different agents. 
For all experiments 3 x 108 platelet (final volume 0.5 ml) were incubated 
with 1.2 x 1010 to 40 x 1010 virus particles at 37°C for 12 hours. The 
amounts of inhibitors used were estimated from the following 
publications and the exact amounts determined by uptake/inhibitor 
concentration dependence studies: gangliosides [28], trypsin and trypsin 
inhibitor [18], EDTA [17], cytochalsin B [29] and dinitrophenol/iodoacetate 
[16]. Preincubation of the virus particles with 50 ~g/ml of either GD1a or 
GT1b (Sigma Chemical Co.) at 37°C for 20 minutes decreased uptake by 
45% and 78% respectively (n=6). Trypsinization by preincubation with 40 
mg/ml of trypsin at 37°C for 20 minutes followed by the addition of 80 
mg/ml soybean trypsin inhibitor inhibited uptake by 70% (n=4). 
Incubation in the presence of 1 mM EDTA, 4 mg/ml cytochalasin B or 2.5 x 
10-4 M 2,4-dinitrophenol and 5 x 10-s M iodoacetate did not inhibit uptake 
(n=2). 
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Gangliosides are known receptors for the HN protein of Sendai virus 
[28]. The addition of suitable gangliosides blocks the binding proteins on 
the virus. Trypsinization of the virus particles cleaves the reactive 
sequence of peptides of the fusion protein that is essential for fusion [18]. 
EDTA chelates divalent cations whose presence are essential for platelet 
phagocytosis [17]. Cytochalasin B alters the plasticity of platelet 
membranes and decreases OCS uptake [29]. The combination of 2,4-
dinitrophenol/iodoacetate inhibits glycolysis and oxidative 
phosphorylation which are necessary to produce energy for phagocytosis 
[16]. 
HPTS Labeled RSVE Uptake. In order to determine whether Sendai 
virus particles were phagocytosed by platelets and subsequently delivered 
to an acidic compartment, the time dependence of the uptake of 
fluorescently labeled (HPTS) reconstituted virus particles was measured by 
fluorimetry. No change in the pH-dependent fluorescence was noted; 
therefore there was no significant RSVE accumulation in acid-containing 
vesicles, such as lysosomes or prelysosomal vesicles . 
Uptake of 1251-labeled RSVE. To study the uptake of RSVE by 
platelets, varying amounts of 1251-labeled reconstituted virus particles 
were incubated with platelets . Assuming that the HN and F proteins are 
25% of the total virus protein [30] and are the only proteins present in 
RSVE, 1 mg of protein should correspond to 5.2 x 109 reconstituted virus 
particles. Using this conversion factor, more RSVE than virus were taken 
up by the platelets (Figure 6). Incubation of 3 x 108 platelets with either 9.9 
x 1010 virus particles or 9.9 x 1010 reconstituted virus particles at 37°C for 12 
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hours, resulted in approximately 125 RSVE per platelet and 50 virus 
particles per platelet. 
Electron Microscopy. Electron microscopy was performed to study the 
effects of HBSS and modified Tyrodes buffer on platelet morphology and 
to investigate the location of the virus particles with respect to the 
platelets. Platelets maintained a discoid shape when suspended in 
modified Tyrodes buffer. However, platelets suspended in HBSS tended to 
have irregular shapes and approximately half had pseudopodia. 
Therefore, even though the amounts of uptake by platelets suspended in 
both buffer are identical, we believe that incubation in modified Tyrodes 
buffer is superior. A number of virus particles were located within the 
open channel system (OCS). Examination of a large number of sections 
(n=30) showed an average of 8 ± 2 virus particles bound to the surface and 
within the OCS of each cell (Figure 7). 
In vitro Assays to Assess Platelet Function. Platelets secreted 15% at 
0.17 hr., 62% at 1 hr. , 64% at 3 hr, 66% at 5 hr., and 65% at 7 hr. of the 
radiolabeled serotonin when incubated with Sendai virus particles and 
18% at 0.16 hr., 19% at lhr., 19% at 3 hr., 20% at 5 hr., and 28% at 7 hr. 
when incubated without Sendai virus particles (n=2). Incubation with 
Sendai virus also resulted in platelet microaggregates ( <15 cells per 
aggregate): 18% at 0.17 hr., 16% at 1 hr., 16% at 3 hr., 15% at 5 hr., and 12% 
at 7 hr. as compared to 1% at 0.16 hr, 2% at 1 hr., 2.5% at 3 hr., 3% at 5 hr., 
and 8% at 7 hr. in the absence of virus particles (n=2). It is interesting to 
note that microaggregation occurred without significant secretion during 
the first several minutes of incubation. Secretion and aggregation in the 
absence of virus particles may have been due to the unfavorable 
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conditions that exist when cells are kept in small polypropylene tubes for 
extended periods of time at 37°C without stirring. In addition secretion 
may have been caused by the presence of imipramine which can induce 
small amounts of leakage. 
DISCUSSION 
Two possible mechanisms of platelet/Sendai virus interaction: viral 
fusion and platelet phagocytosis, were examined. Sendai virus fusion is a 
receptor mediated process in which the virus envelope fuses with the cell 
membrane and the envelope's contents are deposited into the cell's 
cytoplasm. Platelet phagocytosis of particles begins with particle 
sequestration within the OCS and is followed by localization and 
degradation of the particles within acid-containing vacuoles and eventual 
exocytosis of the aqueous components of the particle. Note, platelet 
phagocytosis, as defined in this paper, is not receptor mediated and should 
not be confused with receptor-mediated endocytosis. Fusion was 
determined to be the dominant process. However, binding of the virus 
particles to the platelets was also significant, as shown by the uptake data 
taken at 4°C. 
Initially we examined the interactions of 125I labeled virus or 
reconstituted virus particles with platelets. Uptake values using 125I 
labeled SV or RSVE experiments do not differentiate between fusion and 
phagocytosis and the data reported reflect all processes of uptake including 
binding. Uptake of 125I labeled virus particles was time dependent and 
showed saturation at longer incubation periods. Uptake was also 
dependent on the number of virus particles incubated with the platelets 
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and increased with increasing virus concentration until saturation at high 
concentrations. Platelet uptake of virus particles at 37°C was 
approximately twice that at 4°C. The majority of Sendai virus associated 
with the cells at 4°C were probably bound to the platelets' surfaces since 
fusion and phagocytosis are negligible at this temperature. Uptake values 
for 1251 labeled reconstituted virus particles exceeded those for 125J labeled 
intact virus. Although there is no clear explanation for this difference, 
Harmsen et al. [31] suggested that a disturbance of the membrane lipid 
asymmetry may affect the functional properties of the reconstituted 
proteins. In addition, Lee et al. [32] suggested a possible correlation 
between the fusion capacity of Sendai virus particles and the rotational 
mobility of the F protein; the fusion activity increases with increasing 
mobility. In the native membrane the rotational freedom of the F protein 
may be more restricted than in the RSVE due to the rigidity of the intact 
virus membrane. 
Virus localization within the OCS, as shown by electron microscopy, 
suggested that platelet phagocytosis might be occurring. However, there 
was no accumulation of virus in acid-containing vesicles as detected by 
HPTS, a pH-sensitive probe. Retention of both the aqueous components 
and the protein of the virus is also inconsistent with results expected for 
platelet phagocytosis, as previously shown in studies of platelet 
phagocytosis of liposomes [14]. In addition, preincubation of platelets with 
non-radiolabeled virus resulted in decreased uptake of radiolabeled virus. 
For experiments with similar amounts of liposomes and platelets, where 
uptake by the platelets is believed to occur via phagocytosis, uptake is not 
saturable [14]. Since fusion is receptor m ediated, we believe that blockage 
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of the receptors by unlabeled virus particles or free gangliosides reduced 
the availability of the receptors to the labeled particles and decreased 
fusion and uptake. 
Fusion was monitored using the R1s fluorescence assay. The fusion 
plots of Sendai virus particles with platelets are similar to those seen for 
other cells [8-10]. Fusion showed biphasic kinetics; initially fusion 
increases rapidly over two minutes and then proceeded more slowly until 
the fusion was saturated. The percent fusion decreases with increasing 
amounts of incubated virus and increased with increasing amounts of 
platelets added. The low percent fusion seen at 4°C may represent fusion-
independent transfer of the R1s probe. As expected, fusion was maximal at 
37°C and pH 7.4. 
To further support the hypothesis that fusion is the predominant 
process, the platelets and/ or virus particles were incubated with agents 
known to inhibit fusion or phagocytosis. The addition of the gangliosides 
GD1a and GTlb to the virus particles prior to incubation with the platelets 
inhibited uptake. Trypsinization of the virus particles prior to incubation 
also decreased uptake. However, uptake was not inhibited by incubation 
in EDTA, preincubation of the cells with cytochalasin B or the addition of 
2,4-dinitrophenol and iodoacetate to the platelet solution. Therefore, we 
conclude that the predominant interaction between platelets and Sendai 
virus particles is fusion. 
Reconstituted Sendai virus envelopes have been previously used in 
vitro to deliver drugs to cells (for a general review, 33). Various lipophilic 
and aqueous substances can be introduced during reconstitution which 
can be delivered to various cells via fusion. The results of our platelet 
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function assays and those of Chernesky et al. [1] indicate that incubation 
with Sendai virus particles adversely affects platelet function. Therfore, 
the use of RSVE for drug delivery to platelets may not be feasible unless 
the concentration of RSVE can be kept below that required to induce 
aggregation and secretion. As of now, the concentration dependence of 
platelet secretion and aggregation has not been studied. 
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Figure 1: Incubation time dependence of platelet uptake of 125! labeled 
Sendai virus. 3 x 108 platelets were incubated with 9.9 x 1010 virus at 37°C 
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Figure 2: Sendai virus concentration dependence of platelet uptake of 125J 
labeled virus. 3 x 108 platelets were incubated with varying amounts of 
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Figure 3: Temperature dependence of platelet uptake of 125J labeled virus. 
3 x 108 platelets were incubated with varying amounts of 125J labeled virus 
at 37°C (0) and 4°C (•) for 12.0 hours (n=2). 
164 
165 
Percent CPM tn the Supernatant 
........ N w ~ Vl 0\ 
0 0 0 0 0 0 0 
0 ·~---I . I . I • I . I . 
• a 
N - -
Ml tat --::::r--3 
0 ,_. 
c:: 3~ ~ a -...., (D 
Cl) -
~ • H!H . 
-
QO a l • I I • I • I • 
• a 
Figure 4: Release studies of the protein associated and aqueous probes. 3 x 
108 platelets were preincubated with 9.9 x 1010 3H-inulin labeled RSVE or 
9.9 x 1010 125J labeled virus at 37°C for 12.0 hours. The cells were then 
pelleted, washed twice in buffer and incubated for various incubation 
times at 37°C. The percentages of the 3H-inulin (e) and the 1251 (0) labels 








::l 6 w.. 






0.65 1 .3 1 .95 2 .6 3 .25 3.9 




c l O 0 
til 
::l 8 w... 






1 . 5 2 .25 3 4 .5 5.25 6 
Number of Platelets 
110 -7 ) 
Figure 5: Concentration dependence of fusion. (A) 4.5 x 107 platelets were 
incubated with varying amounts of R1s labeled virus at 37°C (•) and 4°C 
(0) for 30 minutes (n=2). (B) 6.5 x 109 R1g labeled Sendai virus p articles 
were incubated with varying amounts of platelets at 37°C C•) and 4°C (0) 
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Figure 6: Reconstituted virus concentration dependence of platelet uptake 
of 1251-labeled reconstituted virus. 3 x 108 platelets were incubated with 
varying amounts of 125J-labeled reconstituted virus (0) and 125J-labeled 
virus (•) at 37°C for 12.0 hours (n=2). 
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Figure 7: Electron micrograph of a platelet containing virus. 3 x 108 
platelets were incubated with 1 x 1011 virus for 6.0 hours at 37°C. Note the 
virus within the open channel system (n=2). Bar, 0.1 mm. 
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APPENDIX A 
ASSESSMENT OF THE THROMBOLYTIC EFFICACY OF 
LIPOSOME ENCAPSULATED STREPTOKINASE 
B. Cercek, *R. Male, J. Yano, W. Ganz, T. Migita and P. K. Shah 
Cedars-Sinai Hospital, Cardiology Department 
*California Institute of Technoloy 
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ABSTRACT 
The thrombolytic efficacy of streptokinase encapsulated in 1-
palmitoyl 2-oleoyl phosphatidylcholine large unilamellar vesicles (LUV) 
in close-chested dogs 1 hour post-artery occlusion and 15 minutes and 1 
hour post-injection was studied. No evidence was found that liposome 
encapsulation enhances the thrombolytic efficacy of streptokinase. 
INTRODUCTION 
The formation of an occlusive thrombus (clot) within an 
atherosclerotic artery is the principal event which initiates acute 
myocardial infarction (heart attack) (1-3). The vast majority of deaths 
following myocardial infarction occur within hours of the initial occlusive 
event (4). Canine studies have shown that 30-40% of the infarcted area is 
lost at 40 minutes, and 80-90% is lost at 3 hours (5). Though one must be 
cautious in applying these results to humans, clinical studies in humans 
do support the contention that myocardium loss is rapid and significant 
before 3-6 hours (6-8). 
Recent therapies for the rapid restoration of vessel patency, along with 
decreased mortality and improved ventricular function, have included 
the use of fibrinolytic agents, especially plasminogen activators. 
Fibrinolytic agents convert plasminogen to plasmin which initiates lysis of 
the thrombus. Plasminogen activators such as streptokinase (SK), 
urokinase, tissue plasminogen activator (t-PA) and genetically engineered 
one- and two-chain versions of t-PA and urokinase have been 
administered effectively by intravenous infusion. However, the risk of 
hemorrhage, as a result of treatment with any of these thrombolytic 
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agents, is significant. For patients treated with SK or urokinase, the risk of 
bleeding complications is between 23 and 47% (9). 
Although SK can induce immunological side-effects (10) and cause 
hemorrhaging (9), it is currently the least expensive and most widely used 
plasminogen activator . In order to decrease unwanted side-effects, 
prevent serum protein inactivation and enhance myocardium uptake, 
several investigators have encapsulated SK in liposomes (11,12) . 
Encapsulation of SK in 1-palmitoyl 2-oleoyl phosphatidylcholine large 
unilamellar vesicles (LUV) has been shown to decrease the in vitro clot 
dissolving time by 24% in the presence of plasma proteins, as compared to 
free SK (11). Caride et al. reported liposome accumulation in canine 
ischemic myocardium 24 hours following coronary occlusion in dogs (13). 
Accumulation was dependent on the net charge of the liposome 
membrane. Positively charged egg phosphatidylcholine:cholesterol: 
stearylamine (7:1:2 mole ratio) multilamellar vesicles (ML V) accumulated 
within the infarcted myocardium; negatively charged egg 
phosphatidylcholine:cholesterol: dicetylphosphate (8:1:1 mole ratio) MLV 
did not accumulate. Cole et al. found no evidence of accumulation of 
phosphatidylcholine: cholesterol:stearylamine (8:1:1 mole ratio) small 
unilamellar vesicles (SUV) within canine infarcted myocardium 5 hours 
post occlusion and 1 hour post injection (5). Nguyen et al. reported that 
injection of SK containing 1-palmitoyl-2-oleoyl phosphatidylcholine LUV 
into dogs decreased the reperfusion time (time needed to restore blood 
flow) by 50%, as compared to free SK (12). 
Accumulation of liposomes in infaracted myocardium at 24 hours, as 
studied by C aride et al. (13) is interesting, but of little clinical use . 
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Accumulation at shorter times is questionable, since there are conflicting 
data from studies which used vastly different protocols. The present study 
was designed to establish definitively whether liposome encapsulated SK 
(LESK) is an effective treatment for occlusive thrombi during shorter time 
periods. The average reperfusion time for LESK treatment reported by 
Nguyen et al. was 32 ± 28 minutes. Therefore we chose to examine the 
efficacy of 1-palmitoyl-2-oleoyl phosphatidylcholine LUV encapsulated SK 
treatment in dogs within 15 and 60 minutes post injection. 
MATERIALS AND ME1HODS 
Liposome Encapsulated SK (LESK) Preparation. Sixty-five mg of 1-
palmitoyl-2-oleoyl phosphatidyl-choline (POPC) (Avanti Polar Lipids) in 
chloroform was taken to dryness in a 100 ml round bottom flask with a 
Buchler "Rotovap" apparatus and was dried under vacuum overnight. 
The lipid film was resuspended in 4 ml of Tyrodes buffer containing 106 
units of SK (KabiVitrum, Sweden), Vortex mixed and sonicated for 15 
minutes with a Heat Systems-Ultrasonics sonicator with a microprobe. 
During sonication the tube was emersed in ice water to prevent solution 
heating. Unencapsulated SK was removed by centrifugation at 110,000 g 
for 30 minutes using a ficoll gradient. The ficoll gradient consisted of 
three layers (from bottom to top): (1) 1 ml of 30% ficoll mixed with 0.5 ml 
liposomes was layered on the bottom of the tube, (2) 2.5 ml of 10% ficoll 
and (3) 0.75 ml Tyrodes buffer. Liposomes were stored at 4°C and warmed 
to room temperature prior to use. The average liposome diameter was 100 
± 20 nm, as assessed by photon correlation spectroscopy. 
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Streptokinase Encapsulation Efficiency. The Peterson modification of 
the Lowry protein assay (14) with a bovine serum albumin standard and 
without trichloroacetic acid precipitation was used to determine the 
amounts of protein added and encapsulated. The encapsulation 
efficiencies ranged from 25 to 30%. 
Streptokinase Activity Assay. A chromogenic substrate assay (Kabi 
Diagnostica, Franklin, Oh.) was performed to determine the activity of the 
liposome encapsulated SK. S-2251, a chromogenic substrate is hydrolyzed 
by plasmin, thus liberating the chromophoric group p-nitroaniline. 
Standards and samples were prediluted to 1000 units/ml and then further 
to 1:50, 1:100 and 1:200. One hundred and twenty five f.!g of S-2251 and 125 
units of plasminogen were mixed with the standards or liposomes, pre-
dissolved with 10% triton X-100, and allowed to sit at room temperature 
for 15 minutes. A volume of 50 Jll of citrate buffer pH 3.0 was added to 
stop hydrolysis . The absorbances at 405 nm, which are directly 
proportional to the streptokinase activity, were determined. 
In vitro Activity of free SK. Samples with 50 units of thrombin and 4 x 
1Q-5 moles of CaCl2 were added to 1 ml of plasma and incubated for 2 
hours at room temperature. The resulting clot was removed, rinsed in 
isotonic saline and weighed. The clot was then resuspended in plasma 
with 1,000 units/ml free or encapsulated streptokinase. 
In vivo Experimental Preparation. The study was performed in 
closed-chested mongrel dogs, 16 to 28 kg in body weight, anesthetized with 
30 mg/kg sodium pentobarbital and additional doses as needed. The dogs 
were intubated and artificially ventilated with room air with use of a 
Harvard respirator . An electrocardiographic lead was continually 
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monitored. Both the jugular and femoral veins were exposed and a 25 
mm long copper coil of slightly conical shape, 2 mm in outside diameter, 
was inserted into each vein. The coils were weighed before insertion. One 
hour after implantation the coils with the thrombi were removed, 
weighed again to determine the initial thrombus weight, and then 
inserted into the dissected carotid and femoral arteries of the same animal. 
Shortly before insertion of the coils, the exposed femoral arteries and all 
their branches had been ligated. After insertion the main femoral artery 
proximal to the coil and one side branch distal to the coil were released to 
permit blood flow around the thrombus, which was evidenced in all 
experiments by the presence of distinctly papable pulsations in the distal 
side branch. All other branches remained ligated during the study (Figure 
1 ). Ten thousand units per kg weight of dog of free SK and LESK were 
injected i. v . . The coils were removed 15 minutes or 1 hour post-injection 
and weighed; the percent weight decreases were determined. 
RESULTS 
In vitro lysis. The average size of the clot formed was 490 ± 40 mg. 
Incubation with 2000 units SK or LESK for 1 hour reduced the clot weight 
by 76 ± 6.0% (n=4) and 48 ± 6.6%, respectively (n=4). 
In vivo activity. In all experiments the weight of the thrombus 
decreased upon addition of free SK. The average percent lysis, defined as 
01 l . weight clotinitial -weight clotfina1 26 7 + 13 2 Th 10 ys1s = . , was . _ . . e average 
weight clotinitial 
percent lysis 15 and 60 minutes post-injection of LESK were -4.3 ± 19.2 and 
-9.6 ± 7.9, respectively. The results of these studies are summarized in 
Table 1. 
DISCUSSION 
From this study, we conclude that liposome encapsulated SK does not 
significantly decrease thrombus weight 1 hour post-occlusion and 15 
minutes or 1 hour post-injection. Our results are contrary to data reported 
by Nguyen et al. (12), which showed significant decreases in reperfusion 
times for LESK, as compared to SK. According to Nguyen et al. , the 
reperfusion times and thrombus weight remaining were 78 ± 43 minutes 
and 28.6 ± 31.8 mg and 32 ± 28 minutes and 3.4 ± 4.3 mg for free and 
liposome encapsulated SK, respectively. Some differences in the protocols 
of the two experiments should be noted that may be responsible for the 
discepencies . Nguyen et al. prepared their liposomes by the addition of an 
n-octyl-p-D-glucopyranoside (OG)/SK mixture and dialysis. OG is a 
detergent, and it is uncertain whether it has any thrombolytic activity; the 
residual amount of OG was not reported. The size and encapsulation 
efficiencies of the liposomes and estimated percent SK residing within the 
interior, as compared to that bound to the surface, were comparable to 
those measur~d in this study. Nguyen et al. prepared their clots by the 
repeated injection of thrombin. Decreases in reperfusion times were 
reported as evidence of thrombolysis . However, the initial weights of the 
thrombi were not measured and the thrombi were not held in place. 
Therefore it is possible that the decreased reperfusion times were due to 
fragmentation of the thrombus rather than lysis. 
For effective thrombolysis using LESK, the liposomes must 
accumulate at the site of the occlusion and the streptokinase must be 
released. The half-life of intact POPC liposomes in plasma at 37°C is on the 
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order of a few minutes; therefore the liposomes must accumulate within 
this time period. Otherwise the efficacy of LESK should be similar to or 
less than that for free SK, since liposomes also tend to rapidly accumulate 
within the reticuloendothelial system (RES). Future studies should 
examine the biodistributions of POPC liposomes as well as the SK. The 
addition of antibodies or other ligands to the surface of the liposomes to 
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(A) (B) (C) 
Figure 1: Ligation of the artery and side branches prior to (A), during (B) 
and after (C) insertion of the coppper coil. 
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DOG SK LESK ave.% Lysis number of clots 
1 X 34.4 ± 12.5 4 
2 X 16.4 ± 2.5 4 
3 X 5.8 ± 7.6 2 
4 X -6.5 ± 19.9 4 
5 X -7.1 ± 24.7 4 
6 X -9.6 ± 7.9 3 
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Table 1: Free and liposome encapsulated SK were injected i. v . . The 
percent lysis was measured 15 minutes (Dogs 1-5) and 60 minutes (Dog 6) 
• . . 0/ 1 . weight clotinitial - weight clot final 




USEFUL ASSAYS FOR THE JDB GROUP 
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2.2 g (NB4)t)Mo7024 · H20 
14.3 ml cone. H2S04 
dilute to 1 liter with deionized H20 
10% w /w ascorbic acid (stable 2-3 weeks in refrigerator) 
712 mg Na2HP04 · 2H20 in 100 ml deionized H20 (store in 
refrigerator) 
Dilute 1 ml of stock to 100 ml (0.4 nmol/ul) for use in the assay 
Procedure: 
Reagents: 
1. Pipet Na2HP04 · 2H20 standards of 0, 20, 40, 60, 80, 100 nmol and 
samples in duplicate 
2. Add 0.4 ml of 70% HCl04 to samples and standards 
3. Heat 30 minutes at 180-190°C in a heating block 
4. Lea t cool 15 minutes 
5. Add 4 ml molybdate reagent 
6. Add 0.5 ml ascorbic acid solution 
7. Vortex and let clear 10 minutes in a boiling water bath 
8. Measure As12 nm 
Peterson Modification of the Lowry Protein Assay 
CTC solution 
20% Na2C03 
add equal volume of a 0.2% CuS04. SH20/ 0.4% sodium tartate 
solution (stable > 2 months at room temperature) 
10% Sodium dodecylsulfate (SDS) 
0.8NNaOH 
2 N Folin-Ciocalteu phenol reagent 
BSA, fraction V, 1 mg/ml BSA with 1 mg/ml NaN3 (keep in 
freezer) 
Procedure: 
1. Pipet BSA standards of 10, 20, 40 mg and samples in duplicate 
Reagents: 
2. Add equal volumes of CTC, SDS, NaOH solutions and water 
(solution A) 
3. Add 0.5 ml deionized H20 and 0.5 ml solution A to standards 
and samples 
4. Let sit 10 minutes 
5. Prepare a 1:5 Folin-Ciocalteu soultion:water solution 
6. Add 0.25 ml Folin-Ciocalteu phenol solution; vortex 
7. Let sit 30 minutes 
8. Measure A750 nm 
Sendai Virus Preparation 
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Phosphate Buffered Salt (PBS): 0.90% NaCl: 0.12% Na2HP04·7H20: 
0.013% NaH2P04·H20 w /win water, pH 7.3 
Procedure: 
Reagents: 
1. Inject 10 day old chicken eggs with 2 j...LA of a 2j...Lg/ml virus 
solution containing 1% penicillin and 1% streptomycin (per egg); 
make sure the eggs are fertilized 
2. Incubate at 37°C 
3. Freeze the 13 day old eggs at -20°C for 1 hr to prevent bleeding 
4. Remove the top of the shell and carefully pipet out the fluid 
5. Centrifuge the fluid in 250 ml centrifuge bottles at 3500 rpm (GSA 
rotor) for 30 minutes 
6. Discard pellet; centrifuge the supernatant in 25 ml tubes at 25,000 
rpm (SS34 rotor) for 45 minutes 
7. Discard the supernatant; resuspend the pellet with 1.5-2 ml of 
PBS using a 15 gauge syringe 
8. If there are still red blood cells present repeat steps 6 and 7 
9. Store the virus at -70°C. 
Red Blood Cell Ghost Preparation 
Prelysis Buffer 




5 mM Na2HP04 
pH8.0 
KNP Buffer 
120 mM KCl 
30 mM NaCl 





1. Add 15 ml RBC to an Erlemyer flask emersed in ice 
2. Add the 20 ml of prelysis buffer 
3. Stir for 15 minutes 
4. Centrifuge in a SS34 rotor at 5500 rpm for 12 minutes at 10°C 
5. Remove the supernatant 
6. Add 100 ml of lysis buffer to the pellet; suck the solution into a 
pi pet 10-15 times 
7. Place in an Erlemyer flask in ice and stir for 30 minutes 
8. Centrifuge in a SS34 rotor at 15,000 rpm for 15 minutes at 10°C 
9. Repeat steps 6-8 two more times 
10. Remove the supernatant 
11. Add 35 ml of the lysis buffer to the pellet; suck the solution into 
a pipet 10-15 times 
12. Cenu J.mge in a SS34 rotor at 12,000 rpm for 20 minutes 
13. Remove the supernatant 
14. Add 10 ml of KNP solution; 0.01 ml of a 1.0 M solution of 
MgS04 
15. Incubate at 37°C for 45 minutes 
16. Store the ghosts on ice or in the refrigerator 
10% SDS Gel Electrophoresis 
Stock solution 
40 g acrylamide 
1.06 g methylene-bis-acrylamide 
diluted in 100 ml distilled water 
Separating gel 
5 ml stock solution 
5 ml of 1.5 M tris·HCl pH 8.8 
10 ml H20 
200 J..l.A of 10% SDS 
100 J..l.A of a 10% solution of ammonium persulfate solution 
(freshly prepared) 
7.5 J..l.A tetramethylenediamine, TEMED (add immediately before 
use) 
Concentrating gel 
1 ml stock solution 
3 ml of 0.5 M Tris·HCl pH6.8 
4mlH20 
80 f..lA of 10% SDS 
100 f..lA of a 10% solution of ammonium persulfate solution 
(freshly prepared) 
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8 M urea 
62.5 mM Tris·HCl pH 6.8 
0.01% bromophenol blue 
Running Buffer 
144 g glycine 
10 g SDS 
30 g Tris·HCl 
dilute in 1 liter water, final pH=8.8 
Staining solution 
0.2% Coomassie blue 
25% methanol 
10% glacial acetic acid 
Destaining Solution 
25% methanol 
10% glacial acetic acid 
Procedure: 
1. Clean glass plates with soap and water followed by ethanol 
2. Apply vaseline to the edges; place plastic tabs; put plates 
together and hold together with clamps 
3. Prepare the separating gel (usually double the recipe); stir 30 
times with a spatula 
4. Tip the plate and add the separating gel; add 5 ml butanol 
saturated with water to break the bubbles 
5. Cover with Saran wrap; let sit 2-2.5 hours 
6. Remove the butanol 
7. Prepare the concentrating gel; stir 30 times with a spatula 
8. Tip the plate and add the concentrating gel 
9. Add the comb at an angle; press gently to remove air bubbles 
10. Cover with Saran wrap; let sit for 2 hours 
11. Remove the comb carefully 
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12. Remove clips from the bottom of the plates 
13. Clip the plates to the rack 
14. Dilute the running buffer (1:10) correct pH to pH 8.8 
15. Add the running buffer 
16. Remove air bubbles 
17. PREPARE SAMPLE 
Add 75-100 111 of a 72% solution of trichloroacetic acid to 0.5-1.0 
ml sample; mix 
Place on ice for 1 hour 
Centrifuge in an Eppendorf centrifuge at 9000 rpm for 10 
minutes at 10°C 
Remove the supernatant 
Add 10 111 of 1 M NaOH; add 50-60 111 of sample buffer to the 
pellet 
Boil 3 minutes in a water bath 
18. Pipet -60 1111 lane of standard or sample 
19. Plugs in leads 
20. In concentrating gel run at 100 mV; lower current for separating 
gel 
21. Remove plugs 
22. Remove the gel 
23. Stain; destain 
